Cationic liposomes for cancer immunotherapy

ABSTRACT

Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the filing date of U.S.application Ser. No. 62/208,344, filed on Aug. 21, 2015, the disclosureof which is incorporate by reference herein.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH/DEVELOPMENT

This invention was made with government support under grant Nos.U54-CA151668 and U54-CA143837 awarded by the National Institutes ofHealth. The government has certain rights in the invention.

FIELD OF THE DISCLOSURE

The present disclosure relates to the fields of molecular biology,nanotechnology, immunotherapy, and medicine. Nanoparticle compositionshave been developed for use in a variety of therapeutic and prophylacticindications. In particular, positively-charged, cytotoxic nanoparticlesloaded with immune modulators exhibit uptake by mammalian cancer cells,resulting in cancer cell death and/or an increased release of cancerantigens following direct injection to a population of cancer cells. Inexemplary embodiments, immune modulators, such as the toll-like receptor(TLR)-4 ligand monophosphoryl lipid (MPL)-A, and Interleukin (IL)-12,have been shown to stimulate antigen presenting immune cells and Tcells, to support the development of anti-cancer immunity.

BACKGROUND

The goal of cancer immunotherapy is to boost or restore immune functionfor effective recognition of antigens associated with aberrant cells.The range of immunotherapy approaches is broad and includes antibodytherapy (Lan et al., 2013), cytokine delivery to stimulate a passiveimmune response (Wayteck, et al., 2013; Jaime-Ramirez et al., 2011), exvivo stimulation of autologous immune cells that are subsequentlyadministered to a patient (Phan et al., 2013), the use of toxicchemotherapy adjuvants for stimulating an immune response (Wan et al.,2012), and formulations with antigens combined with alum, emulsions,liposomes, immune stimulating complexes (Audibert, 2003), or polymericnanoparticles (Craparo and Bondi, 2012).

Beyond protective transport and sustained release of therapeutics,nanoparticles have intrinsic properties that affect biological outcomes.As an example, the vaccine adjuvant alum, thought to function as a depotfor sustained antigen release, induces cytotoxic effects leading to therelease of uric acid and recruitment of immune cells to the site ofinjection (Kool et al., 2008). Alum favors T helper 2 (Th2) immuneresponses, which induce B cells to produce neutralizing antibodies(Rimaniol et al,, 2007; Mori et al., 2012; Brewer, 2006). However,effective cancer immunotherapies require Th1 cytokines to arrest tumorgrowth, specifically IFN-γ and TNF-α (Braumuller et al., 2013).

Similar to alum, cationic liposomes have inherent cytotoxicity, inducingcell death and stimulating immune cell infiltration to the site ofinjection or accumulation. In contrast to alum, which relies on surfaceabsorption for binding of MPL, liposomes incorporate MPL into the lipidbilayer. Previously, it was reported that MPL-liposomes suppress tumorgrowth in a 4T1 immune competent murine model of breast cancer, unlikean equivalent dose of free MPL (Meraz et al., 2014). In addition torecruiting and activating immune cells, tumor cell damage caused by thecationic liposomes is proposed to release endovenous tumor antigens,directing the immune response against cancer cells. The large pool ofendogenous tumor antigens creates an array of epitopes for immunerecognition. The adjuvant effects of cationic liposomes are supported byYan et al. (2007) who demonstrated by microarray mRNA analysis thatDOTAP liposomes up-regulate chemokines, including CCL2, CCL3, and CCL4,in dendritic cells (DC). Barnier-Quer et al. (2013) demonstrated thatincorporation of cholesterol in the bilayer of cationic liposomesenhances their adjuvant effect. Using porous silicon microparticles, itwas previously shown that particle presentation of adsorbed MPLincreases particle uptake by DC; elevated DC expression ofco-stimulatory and major histocompatibility complex (MHC) class I and IImolecules; increased migration of DC to the draining lymph node; andenhanced associations between DCs presenting the ovalbumin peptideSIINFEKL and T cells from OT-1 mice (Meraz et al., 2012).

SUMMARY

The present disclosure overcomes limitations in the art by providing, inan overall and general sense, compositions comprisingpositively-charged, cytotoxic nanoparticles loaded with immunemodulators for use in a variety of diagnostic and therapeuticindications. In one embodiment, the disclosed cationic liposomes exhibitan enhanced uptake by mammalian immune and cancer cells, which resultedin cancer cell death and/or an increased release of cancer antigensfollowing direct injection of the liposomes into a population of cancercells. Loading of these positively-charged, cytotoxic nanoparticles withimmune modulators, such as one or more pattern recognition receptorsincluding, without limitation, one or more toll-like receptor (TLR)ligands (e.g., ligands of TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7,TLR-8, or TLR-9), one or more C-type lectin (CLR) receptors, or one ormore NOD-like receptors (NLR)); one or more distinct lipids, and a TypeI cytokine, e.g., an interleukin, stimulates antigen presenting immunecells and T cells, and supports development of anticancer immunity whenadministered to a mammal. In one embodiment, the TLR ligand includes aligand of TLR4 (bacterial outer wall) (e.g., LPS or MPL-A), TLR2 (e.g.,microbial cell wall including but not limited to peptidoglycan,lipoteichoic acid and lipoprotein, lipoarahinomannan, zymosan),TLR7/8(e.g., viral infection: single-stranded RNA or R848), TLR9 (e.g.,microbial DNA: unmethylated CpG oligodeoxynucleotides (ODNs); TLR3(e.g., double-stranded RNA, viral infection: Poly(I:C)), or TLR5 (e.g.,flagellin; gram positive and negative bacteria). In one embodiment, thecytokine includes but is not limited to one or more of IL-12, IL-1,IL-6, IL-8, IL-18, IL-21, TNF-alpha, or interferon gamma. If thecationic liposome comprises two or more distinct lipids, one of thelipids is cationic, e.g., DOTAP is a cationic lipid, and at least one ofthe others is non-cationic, e.g., DPPC or DSPC). Ratios of the two ormore distinct lipids can vary, for example, for two distinct lipids, theratio of a non-cationic lipid, e.g., neutral lipid, to the canonic lipidmay be x:1 wherein x>1, x=1 or x:1 where x<1. In one embodiment, x>1.Values for x are not necessarily whole numbers. In one embodiment, theliposome has three distinct components, one of which enhances thestability of the liposome (e.g., a stabilizing component such ascholesterol or disulfide-linked deoxyribonucleotides (ODNs)). Forexample, non-cationic lipid:stabilizing component:cationic lipid ratiosmay include x:z:1, wherein x and z independently are each>1. Values forx and z are not necessarily whole numbers. In one embodiment, x and z,independently are 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, or 20. In one embodiment, a range of values for thenon-cationic lipid is from 5 to 10. In one embodiment, a range of valuesfor the stabilizing component is from 1 to 5. In one embodiment, a rangeof values for the cationic lipid is from 1 to 5. In one embodiment, thenumerical values in the ratios for non-cationic lipid:stabilizingcomponent:cationic lipid are mole percents that add up to 100 or 10,e.g., 70:20:10 or 8:1:1. In one embodiment, where the numerical valuesadd up to 100, the stabilizing component may have a value from 5 to 35,e.g., 10, 20 or 30. In one embodiment, where the numerical values add upto 100, the cationic lipid may have a value from 5 to 55 or more, e.g.,10, 20, 30, 40, or 50. In one embodiment, where the numerical values addup to 10, the non-cationic lipid may have a value from 3 to 8. In oneembodiment, where the numerical values add up to 10, the stabilizingcomponent may have a value from 1 to 5. In one embodiment, where thenumerical values add up to 10, the cationic lipid may have a value from1 to 5.

In one embodiment, the present disclosure provides cancer vaccineformulations that comprise cationic liposomes presenting one or moreimmunomodulators either on the surface of, or within the body of, thenanoparticles. The resulting compositions facilitate multifunctionalvector vaccines, the ultimate outcome of which is the in situpresentation of one or more tumor antigens (or immunomodulatory agentsincluding one or more “Checkpoint” regulators such as PD-1 and CTLA-4inhibitors, one or more small molecules, FAB fragments, nucleic acids,antibodies, and such like) which facilitate induction of tumor-specificimmunogenicity in an animal.

In certain aspects, the compositions may further optionally include atleast one additional agent, including, without limitation, at least onepenetration enhancer, at least one therapeutic and/or chemotherapeuticagent, at least one targeting moiety, and/or at least one or moresurface-exposed, surface-bound, surface expressed, or surface containedtargeting moieties, either alone, or in combination with one or moreadjuvanting and/or immunomodulatory or immunostimulatory components, orsuch like.

In related embodiments, the disclosure also provides therapeutic and/ordiagnostic kits including one or more of the compositions disclosedherein, typically in combination with one or morepharmaceutically-acceptable carriers, one or more devices foradministration of the compositions to a subject of interest, as well asone or more instruction sets for using the composition in theprevention, the diagnosis, or the treatment of a mammalian condition,disease, disorder, trauma, and/or dysfunction, including, withoutlimitation, one or more cancers, tumors, and such like.

Also provided are methods for providing an active agent to a mammaliandendritic cell comprising administering to the subject, an effectiveamount of one or more of the positively-charged, cytotoxicnanoparticle-based compositions disclosed herein. In certainembodiments, the subject is at risk for, diagnosed with, or suspected ofhaving one or more abnormal conditions, including, for example, one ormore cancers, or other hyperproliferative disorders.

The disclosure also provides a method for administering an active agentto one or more cells, tissues, organs, or systems of a mammalian subjectin need thereof. The method generally involves providing to a mammaliansubject in need thereof, one or more of the compositions disclosedherein in an amount and for a time effective to administer the activeagents contained with the positively-charged, cytotoxic nanoparticles toone or more selected tissues, organs, systems, or cells within or aboutthe body of the subject. In particular embodiments, the subject is ahuman, and the composition comprises positively-charged, cytotoxicnanoparticles adapted and configured to localize to at least a firsttarget site within or about the body of a human patient to which theactive agent is being administered.

In certain methods, the cationic nanoparticle vaccine componentsdisclosed herein may be adapted and configured to bypass or “cross” abiological barrier selected from the group consisting of a hemo-rheologybarrier, a reticuloendothelial system barrier, an endothelial barrier, ablood brain barrier, a tumor-associated osmotic interstitial pressurebarrier, an ionic and molecular pump barrier, a cell membrane barrier,an enzymatic degradation barrier, a nuclear membrane barrier, or anycombination thereof.

In certain embodiments, the cationic nanoparticle compositions may beformulated for pharmaceutical administration, such as in a suspensionthat includes a plurality of cationic nanoparticles, together with oneor more adjuvants, active ingredients, therapeutics, diagnosticreagents, or any combination thereof.

As noted herein, the cationic nanoparticle compositions of the presentdisclosure may be administered to the subject through any one or moreconventional methods for administration, including, without limitation,orally, intranasally, intravenously, subcutaneously, or by directinjection to one or more cells or one or more tissues within or aboutthe body of the subject.

As further described herein, in certain applications, it may bedesirable to contact a population of cells obtained from a subject exvivo with the cationic nanoparticle compositions disclosed herein, andthen, subsequently, to reintroduce the resulting contacted cells intothe body of the subject. Such ex vivo therapy is particularlycontemplated to be useful in introducing the disclosed cationicnanoparticles to populations of cancer cells, followed by addition ofhuman dendritic cells to the apoptotic/necrotic cancer cells, allowingthe active ingredients to be contacted with the cells, and thenreintroducing the cells back into the body of the animal. In oneembodiment, the cells extracted for such ex vivo manipulation will bethose of the actual patient undergoing treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-E. Characterization of liposomes. A) Dynamic light scatteringwas used to assess particle size. The size distribution of MPL-liposomesis shown, with the inset showing the size distribution of controlliposomes. B) 3D atomic force microscopy images show the surfacetopography of an oxidized silicon chip before and after binding ofMPL-liposomes. C) 2D height images showing a homogeneous population ofMPL liposomes. The height of particles lying on the line is displayed inthe spectra in ‘D’. E) Zeta potential of each liposome population.

FIGS. 2A-D. Cytotoxic nature of cationic liposomes. A) Cell death asmeasured by propidium iodide uptake in 4T1 cells following a 24 hrincubation with 2 μg/ml DOTAP liposomes or 1 μg/ml MPL. B) Flowcytometry histograms illustrate the impact of MPL and/or liposomes oncell viability. C) H&E staining of BALB/c 4T1 tumor sections followingtreatment with MPL liposomes. D) TUNEL staining of tumor sectionsfollowing treatment of mice bearing 4T1 tumors with MPL or liposomes.

FIGS. 3A-D. Impact of MPL-liposomes on tumor growth. A) BALB/c micebearing 4T1 tumors were treated with two weekly intratumoral injectionsof control or MPL liposomes beginning on Day 12 after intramammaryinjection of tumor cells (n=5/group; tumor approximately 200 mm³).Caliper-derived tumor measurements were taken every 2-4 days(***p=0.0001 compared to vehicle control; ###p<0.0001 compared toliposome control). B) BALB/c mice bearing 4T1 tumors were also treatedwith two weekly intratumoral injections of free or liposome-encapsulatedMPL beginning on Day 13 after intramammary injection of tumor cells(n=3-5/group), with caliper-derived tumor measurements presented(*p<0.05 compared to vehicle control; #p<0.05 compared to MPL; reprintedwith permission from Public Library of Science¹³]. C) IVIS imaging oftumor cell luciferase expression in mice following intraperitonealinjection with luciferin (150 mg/kg) before and after liposometreatment. D) Mean weight of excised tumors on Day 25.

FIGS. 4A-E. Influence of IL-12 on the therapeutic efficacy of adjuvantliposomes. A) BALB/c mice hearing 4T1 tumors were treated with twoweekly intratumoral injections of free or liposome-encapsulated MPLbeginning on Day 10 after intramammary injection of tumor cells(n=5/group). Caliper-derived tumor measurements are presented (**p<0.001compared to vehicle control; ###p≤0.001 compared to MPL liposomes,++p<0.01 compared to IL-12). B) IVIS imaging of tumor cell luciferaseexpression in mice following intraperitoneal injection with luciferin(150 mg/kg) before and after liposome treatment. C) Photograph ofexcised tumors from three randomly selected mice from each group. D)Mean weight of excised tumors on Day 23. E) Serum cytokine levels incontrol and liposome-treated mice five hr post injection, based onELISA.

FIGS. 5A-B. Cellular phenotype of tumors following adjuvant nanoparticletherapy. A) Immunofluoresence staining of tumor sections from mice twoweeks after initiation of liposome or IL-12 therapy [nuclei blue (DAN),Ki67 red, CD8 red, F4/80 green, CD204 red, 33D1 red, iNOS green]. B)Percentage of immune cells in tumors based on manual, blinded cellcounts in five randomly selected (based on DAPI staining) regions ofinterest.

FIGS. 6A-C. Impact of therapy on distal untreated tumor growth. BALB/cmice were injected with 4T1 cells in each inguinal fat pad (n=5/group).When tumors were palpable, single tumors were treated by intramammaryinjection of liposomes, MPL or IL-12 twice at weekly intervals. A)Caliper measurements of treated and distal tumors (**p<0.01, ***p<0.001,compared to vehicle control). B) Gross weights of excised tumors on Day23 (**p<0.01, ***p<0.001 compared to vehicle control; # p<0.05, ##p<0.01 compared to liposome control). C) IVIS imaging of tumor cellluciferase activity in select BALB/c groups on Day 23.

FIGS. 7A-7G. Tumor vasculature. A) Intravital confocal micrograph of atomato red 4T1 tumor with FITC dextran-filled vessels. B) CT image ofmicrofil visualized tumor vessels. C) Stitched micrographs of CD31antibody-visualized tumor vasculature. D) Masks (pink—necrotic regions,green—vessels) created to map vessel density. E) Enlarged view of aportion of image in D). F-G) Graphs of vessel density and fractionalvascular area.

FIGS. 8A-C. Intensity and localization of V-sense, ¹⁹F emulsion. A) ¹Hand ¹⁹F MR images of cell pellets after V-sense incubation and washing.B) Macrophages after incubation with v-sense. C) MR ¹⁹F, alone andmerged with ¹H, signals from V-sense injected mice treated with controlPBS or IL-12.

FIGS. 9A-C. Confocal microscopy of V-sense tracer penetration in 4T1tumor tissue. A) Maximum intensity projection image showing TexasRed-labeled V-sense at the tumor periphery of treated mice. B) Tumorsections with more prominent V-sense labeling at the tumor periphery. C)V-sense penetration into the central tumor in IL-12 (left) and control(right) mice.

FIGS. 10A-B. Tumor immunocytes. A) Flow dot blots showing gating formyeloid and T cell populations. B) Mean expression of immunocytes intumor.

DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe relevant arts. Although any methods and compositions similar orequivalent to those described herein can be used in the practice ortesting of the present disclosure, including the methods andcompositions are described herein. Singleton and Sainsbury (1994) andHale and Margham (1991) are examples of references that provide one ofordinary skill with the general meaning of many of the terms usedherein. Each of these references is specifically incorporated herein inits entirety by express reference thereto. For purposes of the presentinvention, the following terms are defined below for sake of clarity andease of reference:

In accordance with long-standing patent law convention, the words “a”and “an,” when used in this application (including in the appendedclaims), denote “one or more.”

The terms “about” and “approximately” as used herein, areinterchangeable, and should generally be understood to refer to a rangeof numbers around a given number, as well as to all numbers in a recitedrange of numbers (e.g., “about 5 to 15” means “about 5 to about 15”unless otherwise stated). Moreover, all numerical ranges herein shouldbe understood to include each whole integer within the range.

As used herein, the term “buffer” includes one or more compositions, oraqueous solutions thereof, that resist fluctuation in the pH when anacid or an alkali is added to the solution or composition that includesthe buffer. This resistance to pH change is due to the bufferingproperties of such solutions, and may be a function of one or morespecific compounds included in the composition. Thus, solutions or othercompositions exhibiting buffering activity are referred to as buffers orbuffer solutions. Buffers generally do not have an unlimited ability tomaintain the pH of a solution or composition; rather, they are typicallyable to maintain the pH within certain ranges, for example from a pH ofabout 5 to 7.

As used herein, the term “carrier” is intended to include anysolvent(s), dispersion medium, coating(s), diluent(s), buffer(s),isotonic agent(s), solution(s), suspension(s), colloid(s), inert(s), orsuch like, or a combination thereof that is pharmaceutically acceptablefor administration to the relevant animal or acceptable for atherapeutic or diagnostic purpose, as applicable.

As used herein, the term “DNA segment” refers to a DNA molecule that hasbeen isolated free of total genomic DNA of a particular species.Therefore, a DNA segment obtained from a biological sample using one ofthe compositions disclosed herein refers to one or more DNA segmentsthat have been isolated away from, or purified free from, total genomicDNA of the particular species from which they are obtained. Includedwithin the term “DNA segment,” are DNA segments and smaller fragments ofsuch segments, as well as recombinant vectors, including, for example,plasmids, cosmids, phage, viruses, and the like.

The term “effective amount,” as used herein, refers to an amount that iscapable of treating or ameliorating a disease or condition or otherwisecapable of producing an intended therapeutic effect.

The terms “for example” or “e.g.,” as used herein, are used merely byway of example, without limitation intended, and should not be construedas referring only those items explicitly enumerated in thespecification.

As used herein, the terms “engineered” and “recombinant” cells areintended to refer to a cell into which an exogenous polynucleotidesegment (such as DNA segment that leads to the transcription of abiologically active molecule) has been introduced. Therefore, engineeredcells are distinguishable from naturally occurring cells, which do notcontain a recombinantly introduced exogenous DNA segment. Engineeredcells are, therefore, cells that comprise at least one or moreheterologous polynucleotide segments introduced through the hand of man.

As used herein, the term “epitope” refers to that portion of a givenimmunogenic substance that is the target of, i.e., is bound by, anantibody or cell-surface receptor of a host immune system that hasmounted an immune response to the given immunogenic substance asdetermined by any method known in the art. Further, an epitope may bedefined as a portion of an immunogenic substance that elicits anantibody response or induces a T-cell response in an animal, asdetermined by any method available in the art (see, for example, Geysenet al., 1984). An epitope can be a portion of any immunogenic substance,such as a protein, polynucleotide, polysaccharide, an organic orinorganic chemical, or any combination thereof. The term “epitope” mayalso be used interchangeably with “antigenic determinant” or “antigenicdeterminant site.”

As used herein, “heterologous” is defined in relation to a predeterminedreferenced DNA or amino acid sequence. For example, with respect to astructural gene sequence, a heterologous promoter is defined as apromoter that does not naturally occur adjacent to the referencedstructural gene, but which is positioned by laboratory manipulation.Likewise, a heterologous gene or nucleic acid segment is defined as agene or segment that does not naturally occur adjacent to the referencedpromoter and/or enhancer elements.

As used herein, the term “homology” refers to a degree ofcomplementarity between two polynucleotide or polypeptide sequences. Theword “identity” may substitute for the word “homology” when a firstnucleic acid or amino acid sequence has the exact same primary sequenceas a second nucleic acid or amino acid sequence. Sequence homology andsequence identity can be determined by analyzing two or more sequencesusing algorithms and computer programs known in the art. Such methodsmay be used to assess whether a given sequence is identical orhomologous to another selected sequence.

As used herein, “homologous” means, when referring to polypeptides orpolynucleotides, sequences that have the same essential structure,despite arising from different origins. Typically, homologous proteinsare derived from closely related genetic sequences, or genes. Bycontrast, an “analogous” polypeptide is one that shares the samefunction with a polypeptide from a different species or organism, buthas a significantly different form to accomplish that function.Analogous proteins typically derive from genes that are not closelyrelated.

The terms “identical” or percent “identity,” in the context of two ormore peptide sequences, refer to two or more sequences or subsequencesthat are the same or have a specified percentage of amino acid residuesthat are the same, when compared and aligned for maximum correspondenceover a comparison window, as measured using a sequence comparisonalgorithm or by manual alignment and visual inspection.

As used herein, the phrase “in need of treatment” refers to a judgmentmade by a caregiver such as a physician or veterinarian that a patientrequires (or will benefit in one or more ways) from treatment. Suchjudgment may made based on a variety of factors that are in the realm ofa caregiver's expertise, and may include the knowledge that the patientis ill as the result of a disease state that is treatable by one or morecompound or pharmaceutical compositions such as those set forth herein.

The phrases “isolated” or “biologically pure” refer to material that issubstantially, or essentially, free from components that normallyaccompany the material as it is found in its native state. Thus, anisolated peptide in accordance with the invention in one embodiment doesnot contain materials normally associated with that peptide in its insitu environment.

As used herein, the term “kit” may be used to describe variations of theportable, self-contained enclosure that includes at least one set ofreagents, components, or pharmaceutically-formulated compositions toconduct one or more of the diagnostic methods of the invention.Optionally, such kits may include one or more sets of instructions foruse of the enclosed compositions, such as, for example, in a laboratoryor clinical application.

As used herein, “mammal” refers to the class of warm-blooded vertebrateanimals that have, in the female, milk-secreting organs for feeding theyoung. Mammals include without limitation humans, apes, many four-leggedanimals, whales, dolphins, and bats. A human is an exemplary mammal.

The term “naturally occurring” as used herein as applied to an objectrefers to the fact that an object can be found in nature. For example, apolypeptide or polynucleotide sequence that is present in an organism(including viruses) that can be isolated from a source in nature andwhich has not been intentionally modified by the hand of man in alaboratory is naturally-occurring. As used herein, laboratory strains ofrodents that may have been selectively bred according to classicalgenetics are considered naturally occurring animals.

As used herein, the term “nucleic acid” includes one or more types of:polydeoxyribonucleotides (containing 2-deoxy-D-ribose),polyribonucleotides (containing D-ribose), and any other type ofpolynucleotide that is an N-glycoside of a purine or pyrimidine base, ormodified purine or pyrimidine bases (including abasic sites). The term“nucleic acid,” as used herein, also includes polymers ofribonucleosides or deoxyribonucleosides that are covalently bonded,typically by phosphodiester linkages between subunits, but in some casesby phosphorothioates, methylphosphonates, and the like. “Nucleic acids”include single- and double-stranded DNA, as well as single- anddouble-stranded RNA. Exemplary nucleic acids include, withoutlimitation, gDNA; hnRNA; mRNA; rRNA, tRNA, micro RNA (miRNA), smallinterfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA(snRNA), small temporal RNA (stRNA), and the like, as well as anycombinations thereof.

As used herein, the term “patient” (also interchangeably referred to as“host” or “subject”) refers to any host that can serve as a recipient ofone or more of the therapeutic or diagnostic formulations as discussedherein. In certain aspects, the patient is a vertebrate animal, which isintended to denote any animal species e.g., a mammalian species such asa human being). In certain embodiments, a “patient” refers to any animalhost, including but not limited to, human and non-human primates,avians, reptiles, amphibians, bovines, canines, caprines, cavines,corvines, epines, equines, felines, hircines, lapines, leporines,lupines, murines, ovines, porcines, racines, vulpines, and the like,including, without limitation, domesticated livestock, herding ormigratory animals or birds, exotics or zoological specimens, as well ascompanion animals, pets, and any animal under the care of a veterinarypractitioner.

The phrase “pharmaceutically-acceptable” refers to molecular entitiesand compositions that do not produce an allergic or similar untowardreaction when administered to a human, and in particular, whenadministered systemically. The preparation of an aqueous compositionthat contains one or more active ingredients is well understood by thoseof ordinary skill in the pharmaceutical arts. Typically, suchcompositions are prepared as injectables, either as liquid solutions oras suspensions. Alternatively, they may be prepared in solid formsuitable for solution or suspension in liquid prior to injection.

As used herein, “pharmaceutically-acceptable salt” refers to a salt thatretains the desired biological activity of the parent compound and doesnot impart any undesired toxicological effects. Examples of such saltsinclude, but are not limited to, acid-addition salts formed withinorganic acids, for example, hydrochloric acid, hydrobrotnic acid,sulfuric acid, phosphoric acid, nitric acid, and the like; and saltsformed with organic acids such as, for example, acetic acid, oxalicacid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconicacid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid,pamoic (embonic) acid, alginic acid, naphthoic acid, polyglutamic acid,naphthalenesulfonic acids, naphthalenedisulfonic acids, polygalacturonicacid; salts with polyvalent metal cations such as zinc, calcium,bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium,and the like; salts formed with an organic cation formed fromN,N′-dibenlethylenediamine or ethylenediamine; and combinations thereof.

As used herein, the term “polypeptide” is intended to encompass asingular “polypeptide” as well as plural “polypeptides,” and includesany chain or chains of two or more amino acids. Thus, as used herein,terms including, but not limited to “peptide,” “dipeptide,”“tripeptide,” “protein,” “enzyme,” “amino acid chain,” and “contiguousamino acid sequence” are all encompassed within the definition of a“polypeptide,” and the term “polypeptide” can be used instead of, orinterchangeably with, any of these terms. The term further includespolypeptides that have undergone one or more post-translationalmodification(s), including for example, but not limited to,glycosylation, acetylation, phosphorylation, amidation, derivatization,proteolytic cleavage, post-translation processing, or modification byinclusion of one or more non-naturally occurring amino acids.Conventional nomenclature exists in the art for polynucleotide andpolypeptide structures. For example, one-letter and three-letterabbreviations are widely employed to describe amino acids: Alanine (A;Ala), Arginine (R; Arg), Asparagine (N; Asn), Aspartic Acid (D; Asp),Cysteine (C; Cys), Glutamine (Q; Gln), Glutamic Acid (E; Glu), Glycine(G; Gly), Histidine (H; His), Isoleucine (I; Ile), Leucine (L; Leu),Methionine (M; Met), Phenylalanine (F; Phe), Proline (P; Pro), Serine(S; Ser), Threonine (T; Thr), Tryptophan (W; Trp), Tyrosine (Y; Tyr),Valine (V; Val), and Lysine (K; Lys). Amino acid residues describedherein are preferred to be in the “L” isomeric form. However, residuesin the “D” isomeric form may be substituted for any L-amino acid residueprovided the desired properties of the polypeptide are retained.

As used herein, the terms “prevent,” “preventing,” “prevention,”“suppress,” “suppressing,” and “suppression” as used herein refer toadministering a compound either alone or as contained in apharmaceutical composition prior to the onset of clinical symptoms of adisease state so as to prevent any symptom, aspect or characteristic ofthe disease state. Such preventing and suppressing need not be absoluteto be deemed medically useful.

“Protein” is used herein interchangeably with “peptide” and“polypeptide,” and includes both peptides and polypeptides producedsynthetically, recombinantly, or in vitro and peptides and polypeptidesexpressed in vivo after nucleic acid sequences are administered into ahost animal or human subject. The term “polypeptide” is generallyintended to refer to all amino acid chain lengths, including those ofshort peptides of from about 2 to about 20 amino acid residues inlength, oligopeptides of from about 10 to about 100 amino acid residuesin length, and polypeptides including about 100 amino acid residues ormore in length. The term “sequence,” when referring to amino acids,relates to all or a portion of the linear N-terminal to C-terminal orderof amino acids within a given amino acid chain, e.g., polypeptide orprotein; “subsequence” means any consecutive stretch of amino acidswithin a sequence, e.g., at least 3 consecutive amino acids within agiven protein or polypeptide sequence. With reference to nucleotide andpolynucleotide chains, “sequence” and “subsequence” have similarmeanings relating to the 5′ to 3′ order of nucleotides.

“Purified,” as used herein, means separated from many other compounds orentities. A compound or entity may be partially purified, substantiallypurified, or pure. A compound or entity is considered pure when it isremoved from substantially all other compounds or entities, e.g., is atleast about 90%, at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99%, or greater than 99% pure. A partially or substantially purifiedcompound or entity may be removed from at least 50%, at least 60%, atleast 70%, or at least 80% of the material with which it is naturallyfound, e.g., cellular material such as cellular proteins and/or nucleicacids.

The term “subject,” as used herein, describes an organism, includingmammals such as primates, to which treatment with the compositionsaccording to the present invention can be provided. Mammalian speciesthat can benefit from the disclosed methods of treatment include, butare not limited to, apes; chimpanzees; orangutans; humans; monkeys;domesticated animals such as dogs and cats; livestock such as horses,cattle, pigs, sheep, goats, and chickens; and other animals such asmice, rats, guinea pigs, and hamsters.

As used herein, the term “substantially free” or “essentially free” inconnection with the amount of a component refers to a composition thatcontains less than about 10 weight percent, less than about 5 weightpercent, aor less than about 1 weight percent of a compound. In someembodiments, these terms refer to less than about 0.5 weight percent,less than about 0.1 weight percent, or less than about 0.01 weightpercent.

The term “substantially complementary,” when used to define either aminoacid or nucleic acid sequences, means that a particular subjectsequence, for example, an oligonucleotide sequence, is substantiallycomplementary to all or a portion of the selected sequence, and thuswill specifically bind to a portion of an mRNA encoding the selectedsequence. As such, typically the sequences will be highly complementaryto the mRNA “target” sequence, and will have no more than about 1, about2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, orabout 10 or so base mismatches throughout the complementary portion ofthe sequence. In many instances, it may be desirable for the sequencesto be exact matches, i.e., be completely complementary to the sequenceto which the oligonucleotide specifically binds, and therefore have zeromismatches along the complementary stretch. As such, highlycomplementary sequences will typically bind quite specifically to thetarget sequence region of the mRNA and will therefore be highlyefficient in reducing, and/or even inhibiting the translation of thetarget mRNA sequence into polypeptide product.

Substantially complementary nucleic acid sequences will be greater thanabout 80 percent complementary (or “% exact-match”) to a correspondingnucleic acid target sequence to which the nucleic acid specificallybinds, and may be greater than about 85 percent complementary to thecorresponding target sequence to which the nucleic acid specificallybinds. In certain aspects, as described above, it will be desirable tohave even more substantially complementary nucleic acid sequences foruse in the practice of the disclosure, and in such instances, thenucleic acid sequences will be greater than about 90 percentcomplementary to the corresponding target sequence to which the nucleicacid specifically binds, and may in certain embodiments be greater thanabout 95 percent complementary to the corresponding target sequence towhich the nucleic acid specifically binds, and even up to and includingabout 96%, about 97%, about 98%, about 99%, and even about 100% exactmatch complementary to all or a portion of the target sequence to whichthe designed nucleic acid specifically binds.

Percent similarity or percent complementary of any of the disclosednucleic acid or polypeptide sequences may be determined, for example, bycomparing sequence information using the GAP computer program, version6.0, available from the University of Wisconsin Genetics Computer Group(UWGCG). The GAP program utilizes the alignment method of Needleman andWunsch (1970). Briefly, the GAP program defines similarity as the numberof aligned symbols (i.e., nucleotides or amino acids) that are similar,divided by the total number of symbols in the shorter of the twosequences. Exemplary default parameters for the GAP program include: (1)a unary comparison matrix (containing a value of 1 for identities and 0for non-identities) for nucleotides, and the weighted comparison matrixof Gribskov and Burgess (1986), (2) a penalty of 3.0 for each gap and anadditional 0.10 penalty for each symbol in each gap; and (3) no penaltyfor end gaps.

The term “a sequence essentially as set forth in SEQ ID NO:X” means thatthe sequence substantially corresponds to a portion of SEQ ID NO:X andhas relatively few nucleotides (or amino acids in the case ofpolypeptide sequences) that are not identical to, or a biologicallyfunctional equivalent of, the nucleotides (or amino acids) of SEQ IDNO:X. The term “biologically functional equivalent” is well understoodin the art, and is further defined in detail herein. Accordingly,sequences that have about 85% to about 90%; or about 91% to about 95%;or even about 96% to about 99%; of nucleotides that are identical orfunctionally equivalent to one or more of the nucleotide sequencesprovided herein are particularly contemplated to be useful in thepractice of the disclosure.

Suitable standard hybridization conditions for the present disclosureinclude, for example, hybridization in 50% formamide, 5× Denhardt'ssolution, 5× SSC, 25 mM sodium phosphate, 0.1% SDS and 100 μg/mL ofdenatured salmon sperm DNA at 42° C. for 16 hr followed by 1 hrsequential washes with 0.1× SSC, 0.1% SDS solution at 60° C. to removethe desired amount of background signal. Lower stringency hybridizationconditions for the present disclosure include, for example,hybridization in 35% formamide, 5× Denhardt's solution, 5× SSC, 25 mMsodium phosphate, 0.1% SDS and 100 μg/mL denatured salmon sperm DNA orE. coli DNA at 42° C. for 16 hr followed by sequential washes with 0.8×SSC, 0.1% SDS at 55° C. Those of ordinary skill in the art willrecognize that conditions can be readily adjusted to obtain the desiredlevel of stringency.

The present disclosure also encompasses nucleic acid segments that arecomplementary, essentially complementary, and/or substantiallycomplementary to at least one or more of the specific nucleotidesequences specifically set forth herein. Nucleic acid sequences that are“complementary” are those that are capable of base pairing according tothe standard Watson-Crick complementarity rules. As used herein, theterm “complementary sequences” means nucleic acid sequences that aresubstantially complementary, as may be assessed by the same nucleotidecomparison set forth above, or as defined as being capable ofhybridizing to one or more of the specific nucleic acid segmentsdisclosed herein wider relatively stringent conditions such as thosedescribed immediately above.

As described above, the probes and primers may be of any length. Byassigning numeric values to a sequence, for example, the first residueis 1, the second residue is 2, etc., an algorithm defining all probes orprimers contained within a given sequence can be proposed:

n to n+y,

where n is an integer from 1 to the last number of the sequence and y isthe length of the probe or primer minus one, where n+y does not exceedthe last number of the sequence. Thus, for a 25-basepair probe or primer(i.e., a “25-mer”), the collection of probes or primers correspond tobases 1 to 25, bases 2 to 26, bases 3 to 27, bases 4 to 28, and so onover the entire length of the sequence. Similarly, for a 35-basepairprobe or primer (i.e., a “35-mer), exemplary primer or probe sequenceinclude, without limitation, sequences corresponding to bases 1 to 35,bases 2 to 36, bases 3 to 37, bases 4 to 38, and so on over the entirelength of the sequence. Likewise, for 40-mers, such probes or primersmay correspond to the nucleotides from the first basepair to bp 40, fromthe second bp of the sequence to bp 41, from the third bp to bp 42, andso forth, while for 50-mers, such probes or primers may correspond to anucleotide sequence extending from by 1 to by 50, from bp 2 to bp 51,from bp 3 to bp 52, from bp 4 to bp 53, and so forth.

“Treating” or “treatment of” as used herein, refers to providing anytype of medical or surgical management to a subject. Treating caninclude, but is not limited to, administering a composition comprising atherapeutic agent to a subject. “Treating” includes any administrationor application of a compound or composition of the disclosure to asubject for purposes such as curing, reversing, alleviating, reducingthe severity of, inhibiting the progression of, or reducing thelikelihood of a disease, disorder, or condition or one or more symptomsor manifestations of a disease, disorder, or condition. In certainaspects, the compositions of the present disclosure may also beadministered prophylactically, i.e., before development of any symptomor manifestation of the condition, where such prophylaxis is warranted.Typically, in such cases, the subject will be one that has beendiagnosed for being “at risk” of developing such a disease or disorder,either as a result of familial history, medical record, or thecompletion of one or more diagnostic or prognostic tests indicative of apropensity for subsequently developing such a disease or disorder.

The term “therapeutically practical time period” means a time necessaryfor an active agent to be therapeutically effective. The term“therapeutically-effective” refers to a reduction in the severity and/orfrequency of one or more symptoms, an elimination of symptoms, and/orone or more underlying causes, the prevention of an occurrence of one ormore symptoms and/or their underlying cause, and/or an improvement or aremediation of damage.

A “therapeutic agent” may be any physiologically or pharmacologicallyactive substance that may produce a desired biological effect in atargeted site in a subject. The therapeutic agent may be achemotherapeutic agent, an immunosuppressive agent, a cytokine, acytotoxic agent, a nucleolytic compound, a radioactive isotope, areceptor, and a pro-drug activating enzyme, which may be naturallyoccurring or produced by synthetic or recombinant methods, or anycombination thereof. Drugs that are affected by classical multidrugresistance, such as vinca alkaloids (e.g., vinblastine and vincristine),the anthracyclines (e.g., doxorubicin and daunorubicin), RNAtranscription inhibitors (e.g., actinomycin-D) and microtubulestabilizing drugs (e.g., paclitaxel) may have particular utility as thetherapeutic agent. Cytokines may be also used as the therapeutic agent.Examples of such cytokines are lymphokines, monokines, and traditionalpolypeptide hormones. A cancer chemotherapy agent, such as docetaxel,may also be a therapeutic agent. For a more detailed description ofanticancer agents and other therapeutic agents, those skilled in the artare referred to any number of instructive manuals including, but notlimited to, Hardman and Limbird (2001).

“Treating” or “treatment of” as used herein, refers to providing anytype of medical or surgical management to a subject. Treating caninclude, but is not limited to, administering a composition comprising atherapeutic agent to a subject. “Treating” includes any administrationor application of a compound or composition of the disclosure to asubject for purposes such as curing, reversing, alleviating, reducingthe severity of, inhibiting the progression of, or reducing thelikelihood of a disease, disorder, or condition or one or more symptomsor manifestations of a disease, disorder, or condition. In certainaspects, the compositions of the present disclosure may also beadministered prophylactically, i.e., before development of any symptomor manifestation of the condition, where such prophylaxis is warranted.Typically, in such cases, the subject will be one that has beendiagnosed for being “at risk” of developing such a disease or disorder,either as a result of familial history, medical record, or thecompletion of one or more diagnostic or prognostic tests indicative of apropensity for subsequently developing such a disease or disorder. Assuch, the terms “treatment,” “treat,” “treated,” or “treating” may referto therapy, or to the amelioration or the reduction, in the extent orseverity of disease, of one or more symptom thereof, whether before orafter its development afflicts a patient.

Illustrative embodiments are described below. In the interest ofclarity, not all features of an actual implementation are described inthis specification. It will of course be appreciated that in thedevelopment of any such actual embodiment, numerousimplementation-specific decisions must be made to achieve thedevelopers' specific goals, such as compliance with system-related andbusiness-related constraints, which will vary from one implementation toanother. Moreover, it will be appreciated that such a development effortmight be complex and time-consuming, but would be a routine undertakingfor those of ordinary skill in the art having the benefit of thisdisclosure.

Exemplary Cationic Liposomes

The use of cationic liposome nanoparticle delivery systems permitattachment of immunomodulatory compounds like toll-like receptorligand(s) (TLR-L), interleukins, and such like to the particle surfaceand loading with both antigens and immune-stimulating agents (forexample, in the form of proteins, peptides, small molecules, RNA, DNA,and the like), either free or encapsulated in nanoparticles. Theinventors have demonstrated that the inclusion of immunomodulatoryagents on the surface of, or within the body of the cationicnanoparticle liposomal formulations leads to engagement of TLR on immunecells, resulting in: 1) enhanced particle uptake by immune cells [i.e.,antigen presenting cells (APC), such as dendritic cells]; 2) activationof immune cells (i.e., increased expression of co-stimulatory molecules,cytokine secretion, and surface MHC expression on APC): and 3) enhancedmigration of immune cells to the lymph node for activation of an immuneresponse.

Dendritic cells (DC) process and present antigens to T lymphocytes,inducing potent immune responses when encountered in association withactivating signals, such as pathogen-associated molecular patterns.Using the 4T1 murine model of breast cancer, cationic liposomescontaining monophosphoryl lipid A (MPL) and interleukin (IL)-12 wereadministered by intratumoral injection. The combination of themultivalent presentation of the Toll like receptor-4 ligand MPL andcytotoxic 1,2-dioleoyl-3-trmethylammonium-propane lipids induced celldeath, decreased cellular proliferation, and increased serum levels ofIL-1β and tumor necrosis factor (TNF)-α. Addition of recombinant IL-12further suppressed tumor growth and increased expression of IL-1β,TNF-α, and interferon-γ. IL-12 also increased the percentage ofcytolytic T cells, DC, and F4/80⁺ macrophages. While single agenttherapy elevated levels of nitric oxide synthase 3-fold above basallevels in the tumor, combination therapy with MPL cationic liposomes andIL-12 stimulated a 7-fold increase, supporting the observed cell cyclearrest (loss of Ki-67 expression) and apoptosis (TUNEL positive). Inmice bearing dual tumors, the growth of distal, untreated tumorsmirrored that of liposome-treated tumors, supporting the presence of asystemic immune response.

Cationic liposomes may be formed from a single type of lipid, or acombination of two or more distinct lipids. For instance, onecombination may include a cationic lipid and a neutral lipid, or acationic lipid and a non-cationic lipid. Exemplary lipids for use in thecationic liposomes include hut are not limited to DOTAP, DODAP, DRAB,DOTMA, MV5, DPPC, DSPC, DOPE, DPOC, POPC, or any combination thereof. Inone embodiment, the cationic liposome has one or more of the followinglipids or precursors thereof:

N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride with amonovalent cationic head; N′,N′-dioctadecyl-N-4,8-diaza-10-aminodecanoylglycine amide; 1,4,7,10-tetraazacyclododecane cyclen;imidazolium-containing cationic lipid having different hydrophobicregions (e.g., cholesterol and diosgenin);1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE);3β-[N-(N′,N′-dimethylamino-ethane) carbamoyl) cholesterol (DC-Chol) andDOPE; O,O′-ditetradecanoyl-N-(α-trimethyl ammonioacetyl) diethanol-aminechloride, DOPE and cholesterol, phosphatidylcholine;1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane,1,2-distearoyl-sn-glycerol-3-phosphocholine (DSPC) and cholesterol,1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, DOPE, and1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy [polyethyleneglycol-2000), 1,2-di-O-octadecenyl-3-trimethylammonium propane,cholesterol, and D-α-toco; 1,2-dioleoyl-3-trimethylammonium-propane,cholesterol; 3-β(N′,N′-dimethyl, N′-hydroxyethyl amino-propane)carbamoyl) cholesterol iodide, DMHAPC-Chol and DOPE in equimolarproportion, or1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine:cholesterol,dimethyldioctadecylammonium (DDAB);1,2-di-O-octadecenyl-3-trimethylammoniumpropane;N1-[2-((1S)-1-{(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide(MVL5); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP);1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA);1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC);1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).

Chemotherapeutic Methods and Use

One aspect of the present disclosure concerns methods for using thedisclosed cationic nanoparticle formulations for treating orameliorating the symptoms of one or more forms of cancer. Such methodsgenerally involve administering to a mammal (and in particular, to ahuman in need thereof), one or more of the disclosed cationicnanoparticle-based compositions, in an amount and for a time sufficientto treat (or, alternatively ameliorate one or more symptoms of) cancerin an affected mammal.

In certain embodiments, the cationic nanoparticle formulations describedherein may be provided to the animal in a single treatment modality(either as a single administration, or alternatively, in multipleadministrations over a period of from several hours (hrs) to severaldays or several weeks), as needed to treat the disease. Alternatively,in some embodiments, it may be desirable to continue the treatment, orto include it in combination with one or more additional modes oftherapy, for a period of several weeks to several months or longer. Inother embodiments, it may be desirable to provide the therapy incombination with one or more existing, or conventional, treatmentregimens.

The present disclosure also provides for the use of one or more of thedisclosed cationic nanoparticle compositions in the manufacture of amedicament for therapy and/or for the amelioration of one or moresymptoms of cancer, and particularly for use in the manufacture of amedicament for treating and/or ameliorating one or more symptoms of amammalian cancer.

The present disclosure also provides for the use of one or more of thedisclosed cationic nanoparticle formulations in the manufacture of amedicament for the treatment of cancer, and in particular, the treatmentof human cancers.

Therapeutic Kits

Commercially-packaged kits that included one or more of the disclosedcationic nanoparticle formulations along with instructions for using thenanoparticles in a particular treatment modality also represent anotherembodiment of the disclosure. Such kits may further optionally includeone or more additional anti-cancer compounds, one or more diagnosticreagents, or one or more additional therapeutic compounds,pharmaceuticals, or such like.

The kits may be packaged for commercial distribution, and may furtheroptionally include one or more delivery devices adapted to deliver thecationic nanoparticle composition(s) to an animal (e.g., syringes,injectables, and the like). Such kits typically include at least onevial, test tube, flask, bottle, syringe, or other container, into whichthe pharmaceutical composition(s) may be placed, and in one embodimentsuitably aliquotted. Where a second pharmaceutical is also provided, thekit may contain a second distinct container into which this secondcomposition may be placed. Alternatively, a plurality of pharmaceuticalcompositions including the cationic nanoparticles disclosed herein maybe prepared in a single mixture, such as a suspension or solution, andmay be packaged in a single container, such as a vial, flask, syringe,catheter, cannula, bottle, or other suitable single container.

The kits of the present disclosure may also typically include aretention mechanism adapted to contain or retain the vial(s) or othercontainer(s) in close confinement for commercial sale, such as, e.g.,injection or blow-molded plastic containers into which the desiredvial(s) or other container(s) may he retained to minimize or preventbreakage, exposure to sunlight, or other undesirable factors, or topermit ready use of the composition(s) included within the kit.

Pharmaceutical Formulations

In certain embodiments, the present disclosure concerns formulation ofone or more cationic nanoparticle systems disclosed herein foradministration to one or more cells or tissues of an animal, eitheralone, or in combination with one or more other modalities of diagnosis,prophylaxis, and/or therapy. The formulation of pharmaceuticallyacceptable excipients and carrier solutions is well known to those ofordinary skill in the art, as is the development of suitable dosing andtreatment regimens for using the particular cationic nanoparticlecompositions described herein in a variety of treatment regimens.

In certain circumstances it will be desirable to deliver the disclosedcompositions in suitably-formulated pharmaceutical vehicles by one ormore standard delivery methods, including, without limitation,subcutaneously, parenterally, intravenously, intramuscularly,intrathecally, intraperitoneally, transdermally, topically, by oral ornasal inhalation, or by direct injection to one or more cells, tissues,or organs within or about the body of an animal.

The methods of administration may also include those modalities asdescribed in U.S. Pat. Nos. 5,543,158; 5,641,515, and 5,399,363, each ofwhich is specifically incorporated herein in its entirety by expressreference thereto. Solutions of the active compounds as freebase orpharmacologically acceptable salts may be prepared in sterile water, andmay be suitably mixed with one or more surfactants, such ashydroxypropylcellulose. Dispersions may also be prepared in glycerol,liquid polyethylene glycols, oils, or mixtures thereof. Under ordinaryconditions of storage and use, these preparations contain a preservativeto prevent the growth of microorganisms.

For administration of an injectable aqueous solution, withoutlimitation, the solution may be suitably buffered, if necessary, and theliquid diluent first rendered isotonic with sufficient saline orglucose. These particular aqueous solutions are especially suitable forintravenous, intramuscular, subcutaneous, transdermal, subdermal, and/orintraperitoneal administration. In this regard, the compositions of thepresent disclosure may be formulated in one or more pharmaceuticallyacceptable vehicles, including for example sterile aqueous media,buffers, diluents, etc. For example, a given dosage of activeingredient(s) may be dissolved in a particular volume of an isotonicsolution (e.g., an isotonic NaCl-based solution), and then injected atthe proposed site of administration, or further diluted in a vehiclesuitable for intravenous infusion (see, e.g., “REMINGTON'SPHARMACEUTICAL SCIENCES” 15^(th) Ed., pp, 1035-1038 and 1570-1580).While some variation in dosage will necessarily occur depending on thecondition of the subject being treated, the extent of the treatment, andthe site of administration, the person responsible for administrationwill nevertheless be able to determine the correct dosing regimensappropriate for the individual subject using ordinary knowledge in themedical and pharmaceutical arts.

Sterile injectable compositions may be prepared by incorporating thedisclosed chemotherapeutic delivery system formulations in the requiredamount in the appropriate solvent with several of the other ingredientsenumerated above, as required, followed by filtered sterilization.Generally, dispersions can be prepared by incorporating the selectedsterilized active ingredient(s) into a sterile vehicle that contains thebasic dispersion medium and the required other ingredients from thoseenumerated above. The compositions disclosed herein may also beformulated in a neutral or salt form.

Pharmaceutically acceptable salts include the acid addition salts(formed with the free amino groups of the protein), and which are formedwith inorganic acids such as, without limitation, hydrochloric orphosphoric acids, or organic acids such as, without limitation, acetic,oxalic, tartaric, mandelic, and the like. Salts formed with the freecarboxyl groups can also be derived from inorganic bases such as,without limitation, sodium, potassium, ammonium, calcium, or ferrichydroxides, and such organic bases as isopropylamine, trimethylamine,histidine, procaine, and the like. Upon formulation, solutions will beadministered in a manner compatible with the dosage formulation, and insuch amount as is effective for the intended application. Theformulations are readily administered in a variety of dosage forms suchas injectable solutions, topical preparations, oral formulations,including sustain-release capsules, hydrogels, colloids, viscous gels,transdermal reagents, intranasal and inhalation formulations, and thelike.

The amount, dosage regimen, formulation, and administration ofchemotherapeutics disclosed herein will be within the purview of theordinary-skilled artisan having benefit of the present teaching. It islikely, however, that the administration of a therapeutically-effective(i.e., a pharmaceutically-effective, chemotherapeutically-effective, oran anticancer-effective) amount of the disclosed compositions may beachieved by a single administration, such as, without limitation, asingle injection of a sufficient quantity of the delivered agent toprovide the desired benefit to the patient undergoing such a procedure.Alternatively, in other circumstances, it may be desirable to providemultiple, or successive administrations of the anti-cancer compositionsdisclosed herein, over relatively short or even relatively prolongedperiods, as may be determined by the medical practitioner overseeing theadministration of such compositions to the selected individual.

Typically, formulations of one or more of the compositions describedherein will contain at least an effective amount of a first activeagent. In one embodiment, the formulation may contain at least about0.001% of each active ingredient, pat least about 0.01% of the activeingredient, although the percentage of the active ingredient(s) may, ofcourse, be varied, and may conveniently be present in amounts from about0.01 to about 90 weight % or volume %, or from about 0.1 to about 80weight % or volume %, or more, e.g., from about 0.2 to about 60 weight %or volume %, based upon the total formulation. Naturally, the amount ofactive compound(s) in each composition may be prepared in such a waythat a suitable dosage will be obtained in any given unit dose of thecompound. Factors such as solubility, bioavailability, biologicalt_(1/2), route of administration, product shelf life, as well as otherpharmacological considerations will be contemplated by one of ordinaryskill in the art of preparing such pharmaceutical formulations, and assuch, a variety of dosages and treatment regimens may be desirable.

Proper fluidity of the pharmaceutical formulations disclosed herein maybe maintained, for example, by the use of a coating, such as e.g., alecithin, by the maintenance of the required particle size in the caseof dispersion, by the use of a surfactant, or any combination of thesetechniques. The inhibition or prevention of the action of microorganismscan be brought about by one or more antibacterial or antifungal agents,for example, without limitation, a paraben, chlorobutanol, phenol,sorbic acid, thimerosal, or the like. In many cases, an isotonic agentmay be included, for example, without limitation, one or more sugars orsodium chloride, or any combination thereof. Prolonged absorption of theinjectable compositions can be brought about by the use in thecompositions of agents delaying absorption, for example withoutlimitation, aluminum monostearate, gelatin, or a combination thereof.

While systemic administration is contemplated to be effective in manyembodiments, it is also contemplated that formulations disclosed hereinbe suitable for direct injection into one or more organs, tissues, orcell types in the body. Administration of the disclosed compositions maybe conducted using suitable means, including those known to the one ofordinary skill in the relevant medical arts.

The pharmaceutical formulations disclosed herein are not in any waylimited to use only in humans, or even to primates, or mammals. Incertain embodiments, the methods and compositions disclosed herein maybe employed using avian, amphibian, reptilian, or other animal species.In some embodiments, however, the compositions of the present disclosuremay be formulated for administration to a mammal, and in particular, tohumans, as party of an oncology regimen for treating one or morecancers. The compositions disclosed herein may also be provided informulations that are acceptable for veterinary administration,including, without limitation, to selected livestock, exotic ordomesticated animals, companion animals (including pets and such like),non-human primates, as well as zoological or otherwise captivespecimens, and such like.

Therapeutic Applications of Multi-Stage Delivery Systems

Nanotechnology is projected to fill the gap between significantscientific advances in the areas of cancer imaging and diagnosis,discovery and development of a plethora of anticancer drugs, and theirtranslation into improvements in cancer management. With optimalanticancer treatment regimens still lacking, novel therapeuticapproaches are being explored to supplement or replace traditional goldstandards, including surgical resection (Finlayson et al., 2003) andradiation therapy (Elshaikh et al., 2005). While the curative potentialof anticancer drugs is indisputable, limitations that hinder clinicaltranslation and success include nonspecific drug delivery. In thissection, various nanoparticles are described that have been successfullyexploited for various therapeutic applications.

Liposomes

Liposomes represent a nanotherapeutic modality that shows immenseclinical potential for drug delivery. These vesicular nanostructures,formed from phospholipid and cholesterol molecules, possess severaladvantages for drug delivery. First, their inner hydrophilic compartmentcan encapsulate water-soluble drugs, as well as therapeutic proteins,DNAs, and siRNAs. Second, with a diameter in the range of 100 nm, thedrug payload can be substantial. Lastly, their functionalization withPEG can grant them with stealth-like properties, avoiding uptake by theRES. A PEGylated liposomal formulation, known as Doxil®, is currently inclinical trials for the treatment of Kaposi's sarcoma (Gabison, 2001).These stealth liposomes have long blood circulation times overnon-PEGylated liposomes, and readily accumulate in tumors due to passivetargeting (Kamaly et al., 2008; Zalipsky et al., 2007).

Another drug that was successfully encapsulated in liposomes isannamycin, a non-cross-resistant anthracycline (Booser et al., 2002).The pre-liposomal annamycin lyophilized powder contains phospholipids(dimyristoylphosphatidyl choline and dimyristoylphosphatidyl glycerol ata 7:3 molar ratio), annamycin (lipid:drug at a ratio 50:1 wt./wt.), andTween-20. The surfactant in the formulation allows for bettersolubilization of the drug, shortening the reconstitution step, as wellas a means to form nano-size carriers without destroying the liposomalstructure (Zola et at., 1996). Similar to doxorubicin, the drugpossesses native fluorescence in the red region. Flow cytometry dataconfirmed loading of annamycin liposomes into porous siliconmicroparticles. Loading resulted in a shift in the mean fluorescentintensity from 3 to 1285 AU. Other liposomal active agents that weresuccessfully loaded into the multi-stage drug delivery system includepaclitaxel, doxorubicin, and siRNA.

Polymer Micelles

Ringsdorf and coworkers worked in the early 1980s on the development ofpolymer micelles as drug delivery vehicles (Gros et al., 1981). Thesespherical, supramolecular constructs, with a size ranging from 10-100nm, are formed from the self-assembly of biocompatible amphiphilic blockcopolymers in aqueous environments (Savic et al., 2003; Matsumura andKataoka, 2009; Nakanishi et al., 2001). The hydrophilic outer portion,typically composed of PEG, forms a hydrating layer, while thehydrophobic core, composed of polymers such as poly(D,L-lactic acid)(PDLLA), poly(ε-caprolactone) (PCL), and polypropylene oxide) (PPO),houses the anticancer agent. The ability of the drug to be encapsulatedwithin the hydrophobic core represents their main advantage, in additionto their innate possession of a PEG hydrophilic corona that preventsopsonization and RES uptake (Satomi et al., 2007), and their small sizewhich leads to their preferential accumulation in tumor tissue throughthe EPR effect.

Currently, several polymeric micelle platforms are being explored inclinical trials. Kataoka and coworkers formulated doxorubicin-containingpolyethylene glycol)-poly(L-aspartic acid) micelles (Nakanishi et al.,2001). This formulation, known as NK911, displayed long bloodcirculation times and nearly tripled the half-life of doxorubicin(Matsumura et al., 2004). Genexol-PM is another micelle formulation inclinical trials, and consists of PEG-PLA micelles that encapsulatepaclitaxel. Findings showed that Genexol-PM was much more tolerable thanthe clinically used formulation of paclitaxel containing Cremephor® EL,a formulation that results in hypersensitivity reactions (Wiemik et al.,1987). As a result, the dose of paclitaxel administered to patientscould be increased, which in turn resulted in enhanced anti-tumorefficacy in patients (Kim et al., 2004; Kim et al., 2004).

To further enhance selective delivery of chemotherapeutics to thelesion, doxorubicin and paclitaxel polymeric micelles have been loadedinto the nanoporous matrix of the silicon microparticles. Fordoxorubicin the best loading was obtained with1,2-distearoyl-phosphatidyl ethanolamine-methyl-poly(ethyleneglycol)anionic micelles loaded into oxidized porous silicon microparticles.

For promoting an understanding of the principles of the disclosure,reference will now be made to the embodiments, or examples, illustratedin the drawings and specific language is used to describe the same. Itwill, nevertheless be understood that no limitation of the scope isthereby intended. Any alterations and further modifications in thedescribed embodiments, and any further applications of the principles ofthe disclosure as described herein are contemplated as would normallyoccur to one of ordinary skill in the art to which the disclosurerelates.

The following example is included to demonstrate illustrativeembodiments of the invention. It should be appreciated by those ofordinary skill in the art that the techniques disclosed in this examplerepresents techniques discovered to function well. However, those ofordinary skill in the art should, in light of the present disclosure,appreciate that many changes can be made in the specific embodimentsthat are disclosed, and still obtain a like or similar result withoutdeparting from the spirit and scope of the invention.

EXAMPLE 1 Materials

MPL from Salmonella enteric serotype Minnesota RE 595 and cholesterol(Sigma grade≥99%) were purchased from Sigma-Aldrich (St, Louis. Mo.,USA). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) Chloride salt wereobtained from Avanti Polar Lipids, Inc. (Alabaster, Ala., USA). MouseNovex Cytokine Magnetic 10-Plex ELISA kits were purchased fromInvitrogen (Grand Rapids, N.Y., USA). 4T1-luc2-td Tomato Bioware® UltraRed mouse mammary cancer cells were purchased from Caliper Life Sciences(Hopkinton, Mass., USA). Recombinant mouse IL-12 was purchased from R&DSystems, Inc. (Minneapolis, Minn., USA).

Animals

BALB/c mice (4-6 wk old) were obtained from Charles River Laboratories,Inc. (Wilmington, Mass., USA). All procedures were performed inaccordance with protocols reviewed and approved by the InstitutionalAnimal Care and Use Committee at Houston Methodist Research Institute.

Preparation and Characterization of Liposomes

DOTAP liposomes were prepared using a molar ratio of 7:3:1 for DPPC:Cholesterol: DOTAP. Lipids (40 mg) were dissolved in a 3 mLChloroform:Methanol (3:1) solution and 250 μg MPL, dissolved inchloroform at 5 mg/mL, was added. Organic solvent was removed byovernight heating at 55° C. in a Hei-Vap Series Heidolph RotatoryEvaporator (Schwabach, Germany). The liposomes were recovered in 2 mLPBS, followed by heating in a waterbath at 52° C. for 3 minutes, thenvortexing for 3 minutes and sonication for 30 seconds. The heat, vortexand sonication cycle was repeated 3 times followed either by finalsonication for 3 minutes to get the final liposome product or byextrusion through dual filters (200 nm), 8×, using a 10 mL ThermobarrelExtruder from Northern Lipids, Inc. (Burnaby, B.C., Canada). Forliposomes containing cytokine, IL-12 was added to the hydrating PBS at afinal concentration of 0.1 mg/mL. Adsorption of IL-12 to the liposomeswas determined by quantitating the amount of IL-12 depleted from thesolvent after removal of the liposomes by centrifugation using the BD™Cytometric Bead Assay for mouse IL-12p70 (San Diego, Calif., USA). Sizeand charge of liposomes were characterized by Dynamic light scattering(DLS) and Zeta Potential analysis using a Malvern Zetasizer(Worcestershire, UK). Liposome size and shape were further characterizedby Atomic Force Microscopy using a Bruker Multimode SPM system (SantaBarbara, Calif., USA), AFM images were acquired in PBS in contact modeusing MLCT cantilevers purchased from Bruker with a spring constant at0.01 N/m.

Cytotoxicity Studies

The cytotoxicity of cationic liposomes to 4T1 breast cancer cells wasevaluated by flow cytometry using propodium iodide (PI). Using a 24 wellplate format, cells were treated with 4 μg control or MPL liposomes, orfree MPL (250 ng) for 24 hours. Cells were released using trypsin andtreated with PI according to manufacturer's protocol (Invitrogen).Samples were analyzed using a LSR II™ Flow Cytometer (BD Biosciences,Mountain View, Calif., USA) equipped with FACSDIVA™ software (2007). Invivo tumor cytotoxicity of cationic liposomes was evaluated in BALB/cmice bearing 200 mm³ 4T1 tumors 24 hours following intratumoralinjection of liposomes (50 μL; 1 mg lipid). Excised tumors were embeddedin paraffin, sectioned, and stained with hematoxylin and eosin or usedfor analysis of apoptosis using the DeadEnd™ Fluorometric TUNEL System(Promega, Madison, Wis., USA).

Multiplex Bead ELISA

Serum cytokines were analyzed 5 hours after intratumoral injection ofliposomes using a mouse cytokine magnetic 10-plex panel kit (Invitrogen,Carlsbad, Calif., USA) for the Luminex® platform. Followingretro-orbital eye bleed, plasma was collected by centrifugation at 1500g for 10 minutes at 4° C. and stored at −80° C. Plates were preparedusing 25 μL/well of the antibody-bound bead. After 2 washes, 50 μL serumand 50 μL assay diluent (or 100 μL standard) were added and plates wereincubated at room temperature for 2 hours on an orbital shaker. Aftertwo washes, 100 μL of biotinylated detector antibody was added to thebeads and they were incubated for an additional hour, followed by twomore washes and the addition of 100 μL streptavidin-RPE for 30 minutes.After a final two washes, beads were suspended in 125 μL wash solutionand inserted into the XY platform of a Luminex MAGPIX Instrument (EMDMillipore, Billerica, Mass., USA). The assay protocol was designed usingxPONENT software and samples were run at 100 events/bead region.

Immunhistochemistry

Tissues were quick frozen in OCT (Tissue-Tek) and stored at −80° C.Tissue sections (10 μm) were fixed with ice-cold acetone for 15 minutesat −20° C. and washed three times with 1× PBS using trays followed byblocking with 5% fetal bovine serum in PBS. Fluorescence-labeledantibodies [e-flour 615 CD8 (clone 53-6.7; 1:50), e-flour 570 Ki-67(clone solA15; 1:100; eBioscience, San Diego, Calif., USA); FITC F4/80(MCA497A488,1:100), Alexa Fluor 647 CD204 (MCA1322; 1:100, AbD Serotec,Raleigh N.C., USA); and 33D1 (1:100, BD Biosciences, San Jose, Calif.;1:500 secondary anti-rat IgG Alexa Fluor® 546; Invitrogen) and iNOS(6/iNOS/NOS; 1:100 BD Biosciences, San Jose, Calif., USA; 1:500anti-rabbit IgG-TRITC, Jackson Immunoresearch Labs, Inc. West Grove,Pa., USA)] were incubated with tissues overnight at 4° C. in thepresence of 5% FBS. Slides were then washed three times with PBS andmounted with ProLong® Gold AntiFade with DAPI (Invitrogen), images weretaken using an A1 Nikon confocal microscope and the percent positivecells were determined by manual counting of four arbitrary regions inrandom samples.

Therapeutic Efficacy Studies

Breast cancer tumors were established in BALB/c mice by intramammaryinjection of 1×10⁵ 4T1-luciferase cells. When tumors reached a mediansize of 100-200 mm³, mice were administered intratumoral injections asfollows: PBS control, Free MPL (6.25 μg), control liposomes (50 μL; 1 mglipid); MPL liposomes (50 μL), and IL-12 (5 μg) with/without MPLliposomes. Tumor growth was monitored by caliper measurements threetimes per week and by luciferase expression measured weekly using theXenogen IVIS-200 System (Perkin Elmer Inc., Waltham, Mass., USA)following intra-peritoneal injection of 75 mg/kg RediJect D-Luciferin(Perkin Elmer Inc.), 24-26 days after initiation of tumor growth, micewere sacrificed, blood was collected by retro-orbital bleeding, andtumor and spleen were collected for immunohistochemical, weight, andsize analysis. Dual tumors were grown in naïve mice using the sameexperimental conditions with intratumoral injection of particles limitedto a single tumor.

Results Characterization of Cationic MPL Liposomes

In order to create localized necrosis for release of tumor antigens anduric acid, a cationic liposome embedded with the TLR-4 ligand MPL wascreated. MPL favors a Type 1 bias, supporting tumor regression, inimmune responses. Dynamic light scattering supported an average diameterof 100.3±0.43 and 103.3±1.85 nm for control and MPL-loaded liposomes,with a poly dispersity index of 0.115±0.014 and 0.28±0.01, respectively.To evaluate the heterogeneity of the population, liposomes were bound toan oxidized silicon wafer, with 3D images of the wafers. The heightimage of the MPL liposomes supported a disperse population that wasuniform in size. A line scan through the height image also supportedhomogeneity in size. The surface potential of the liposomes wasapproximately 47 mV for both control and MPL liposomes, supportinglocalization of MPL in the lipid bilayer. Addition of rIL-12 to theliposomes reduced the surface potential of the liposomes by 7 mV,supporting surface adhesion by rIL-12. Based on detection of unboundIL-12 using a Mouse IL-12p70 Enhanced Sensitivity Flex Set from BDBiosciences (R²=0.987 for standard curve), 34% and 26% of cytokine wasin bound state for control and MPL containing liposomes, respectively.

Evaluation of Liposome Cytotoxicity

To study particle cytotoxicity, 4T1 cells were cultured with 4 μg/mLliposomes for 24 hours and cell death was measured by flow cytometrybased on propodium iodide (PI) uptake. Control and MPL liposomes inducedcell death in 93% and 95% of the cells whereas control and free MPLtreated cells displayed 14% and 16% cell death, respectively (n=3). Flowcytometry histograms of the FL2 orange-red channel show a shift in theentire population of liposome-treated cells.

The in vivo cytotoxicity of the cationic liposomes was studied in BALB/c4T1 orthotopic tumors. When the tumor volumes reached 100-200 mm³,intratumoral injections with PBS, free MPL, or liposomes were performed.After 24 hours, the mice were sacrificed and tumor tissue was analyzedby H&E and TUNEL staining. In contrast to control tumors, clear necroticregions were visible in mice treated with MPL liposomes. Minimal celldeath was present in control and MPL-treated liposomes based on TUNELstaining, while abundant cell death was present after treatment withboth control and MPL liposomes.

Therapeutic Efficacy of Cationic Adjuvant Liposomes

To examine the impact of cationic MPL liposome on breast tumor growth,4T1 orthotopic breast tumors were developed to a size of 100-200 mm³ andintratumoral injections of liposomes were performed once a week for twoweeks. Tumor growth was monitored by caliper measurements and luciferaseexpression using the IVIS Imaging System 200, and tumor weights weremeasured at the end of study. Despite inducing localized cell death,control cationic liposomes did not reduce the rate of tumor growth.However, addition of MPL to the liposomes led to a dramatic reduction intumor growth. Similar to control liposomes, free MPL did not slow tumorgrowth. Bioluminescence imaging of luciferase expression followingluciferin injection using the IVIS 200 imaging system supported thecaliper data, with MPL liposome treatment blocking tumor progression.The mass of excised tumors on day 25 support a significant reduction intumor growth following treatment of MPL liposomes compared to both PBSand control liposome treated mice.

Combination Adjuvant Therapy Increases Blockade of Tumor Growth

To create a microenvironment conducive to cell-mediated immunity thegoal was to boost the immune response further by adding rIL-12 to theliposome cocktail. IL-12, produced by macrophages and dendritic cells,stimulates proliferation and activation of cytotoxic CD8⁺ lymphocytesand NK S cells, leading to the production of IFN-γ, and stimulatingantigen-specific and nonspecific immune responses.

Combined therapy with liposomal MPL and IL-12 (5 μg) was superior toeither agent delivered independently with respect to inhibiting tumorgrowth. While control liposome treated tumors were similar in size totumors in untreated animals, those treated with combination adjuvantwere unchanged from the start of treatment based on caliper measurements(n=5/group) and were undetectable in some animals by bioluminescence(FIG. 4B). An image was created of three randomly selected tumors fromeach group with the mean tumor weight and standard deviation of allanimals in each group. Serum cytokine measurements following single orcombination therapy supported increases in IL-1β , IL-12 and TNF-α byall adjuvant therapy, with a significant enhancement by combination oversingle agent therapy. Only mice treated with IL-12 had an increase inserum IFN-γ.

Changes in the Cellular Phenotype of the Tumor Microenvironment

To study phenotypic changes and impact on cell growth in the tumormicroenvironment following treatment with adjuvant particles, weanalyzed tissues section by immunofluorescence. Cellular proliferation,based on Ki-67 expression, was similar for control and liposome treatedanimals (40%). However, addition of MPL to the liposomes or injectionwith rIL-12 or MPL-IL-12-liposomes blocked proliferation (5-10%). Thepresence of CD8+ T cells in the tumor was negligible in control andliposomes-treated mice (0.8%), as were F4/80 (7%) and iNOS (8%)expressing macrophages. Treatment with MPL-IL-12-liposomes led tosignificant increases in each of these populations (28%, 36%, 54% forCD8+ T cells, F4/80 and iNOS macrophages), as well as in 33D1+ dendriticcells. The percentage of CD204 macrophages were not significantlyaltered in the tumors of mice treated with adjuvant liposomes. Inconclusion, MPL-IL-12-liposomes augment infiltration of cytotoxic Tcells and immune potentiating immune cells, and reduce proliferation ofcells within the tumor.

Single tumor therapy in the presence of dual tumors

MPL-IL-12-liposome therapy was administered to mice by intratumoralinjection to induce cell death, block proliferation, and stimulate acytokine and cellular milieu conducive to anti-cancer immunity. Sincethe presence of pro-inflammatory cytokines increased in the serum oftreated mice, we wanted to test for the presence of systemic anti-cancerimmunity. Growth of distal tumors in mice receiving single tumor therapywas evaluated by caliper measurements of tumor volume, tumor weight andbioluminescence based on luciferase expression in cancer cells. For allgroups, growth of the distal tumor mirrored that to the treated tumor,with MPL-IL-12-liposome therapy inhibiting growth of the tumor.

Discussion

While the addition of MPL to cationic liposomes did not alter thesurface potential of the nanoparticles, addition of IL-12 caused a 7 mVreduction in the zeta potential, supporting surface presentation of thecytokine. The advantage of nanoparticle-based presentation of IL-12 isreduction in serum levels, avoiding exposure to cytotoxic levels andpermitting a more sustained, localized release (Simpson-Abelson et al.,2009). The efficacy of using liposomal nanocarriers to reduce drugtoxicity while enhancing immunity has also been demonstrated for otheragents, such as amphotericin B in the fight against murine leishmaniasis(Daftarlan et al., 2013).

While both control and MPL liposomes were toxic to cancer cells asanticipated, injection of MPL liposomes, unlike control liposomes,reduced cellular proliferation in tumors. The decrease in proliferationmay be attributed to increases in enzymes, such as iNOS which wassignificantly unregulated in tumors following injection withMPL-liposomes. Activation of APC with pathogens or pathogen-specificmolecules (e.g., MPL) activates pathogen recognition receptors (PRRs),leading to release of effector molecules such as nitric oxide (NO)synthase (iNOS). NO has been shown to favor cell cycle arrest,mitochondria respiration, senescence or apoptosis (Napoli et al., 2013).While resting immune cells lack expression of iNOS enzyme, TLRengagement with CD14-LPS (or MPL) complex activates intracellularsignaling, which includes IRAK and MyD88 adaptors, leading to iNOStranscription (Lowenstein and Pabelko, 2004). Herein it was demonstratedthat MPL liposomes and IL-12 induce small increases in iNOS expression(3-fold), while combination therapy with IL-12 and MPL liposomessynergistically increase iNOS expression (7-fold).

In addition to releasing tumor antigen complexes, dying cancer cellsrelease uric acid and lysosomal enzymes. These cellular components, aswell as MPL, activate the Nod-like receptor protein 3 (NLRP3)inflammasome (Martinon et al., 2006; Hornung et al., 2008). While NLRP3activation has been linked to infiltration by DC and macrophages, we didnot see significant increases in either 33D1⁺ DC or F4/80⁺ macrophagesfollowing treatment with MPL-liposomes. However, when IL-12 wasintroduced into the liposomal formulation there were large increases inDC, F4/80⁺ macrophages and CD8⁺ T cells. NLRP3 activation stimulatessecretion of IL-1β and IL-18 (Dinarello, 2006). We previouslydemonstrated that porous silicon particle-based presentation of MPL inmice bearing 4T1 tumors augments its ability to increase serum IL-1βlevels, as well as other pro-inflammatory cytokines including IL-12,TNF-α and IFN-γ (Meraz et al., 2012). In this study, MPL liposomessimilarly increased serum levels of IL-1β, IL-12, and TNF-α. Addition ofIL-12 lead to significantly greater increases in each of these cytokinesand stimulated production of INF-γ.

Cytokines patterns elicited by activated T cells favor eithercell-mediated immunity (i.e., T helper (Th)-1 biased), characterized byIFN-γ, IL-2 and TNF-α, or humoral immunity (Th-2 biased), characterizedby secretion of IL-4, IL-5, IL-6 and IL-10. IL-12 has potent anti-tumoreffects and has been shown to direct immune reactions from Th-2 to Th-1(Manetti et al., 1993; Sypek et al., 1993). As stated, IL-12 enhancedproduction of Th-1 cytokines and increased cytolytic T cells, DC andF4/80⁺ macrophages, as well as enhancing production of iNOS. Inratumoraladministration of combination IL-12 and MPL liposomes completely blocked4T1 tumor growth. Combination liposomal therapy was able to inducesimilar reductions in tumor growth in both treated and distal tumors,suggesting a systemic immune response. Future studies will seek todifferentiate specific anti-tumor immune responses from those resultingfrom general immune activation (e.g., cancer cell death due to TNF-α),and will seek to optimize particle-based accumulation of cytokines inthe tumor, with an emphasis on studying dose effects and controlled,sustained presentation of cytokines for an optimal anti-cancer responsewith minimal cytotoxicity.

EXAMPLE 2

Adjuvant Cationic Liposomes Presenting MPL and IL-12

This example describes the elicitation of cancer-specific de novo hostimmune responses through injection of tumors with cationic adjuvantliposomes. The in vivo immunomodulatory properties of liposomescontaining MPL and recombinant IL-12 (rIL-12) were examined using animmune competent 4T1 mouse model of breast cancer. The impact ofadjuvant liposomes on cell viability and tumor growth was examined, aswas the impact of the particles on the cytokine milieu and immune cellphenotype of the tumor.

Dendritic cells (DC) process and present antigens to T lymphocytes,inducing potent immune responses when encountered in association withactivating signals, such as pathogen-associated molecular patterns.Using the4T1 murine model of breast cancer, cationic liposomescontaining monophosphoryl lipid A (MPL) and interleukin (IL)-12 wereadministered by intratumoral injection. Combination multivalentpresentation of the Toll like receptor-4 ligand, MPL, and cytotoxic1,2-dioleoyl-3-trimethylammonium-propane lipids induced cell death,decreased cellular proliferation, and increased serum levels of IL-1βand tumor necrosis factor (TNF)-α. Addition of recombinant IL-12 furthersuppressed tumor growth and increased expression of IL-1β, TNF-α, andinterferon-γ. IL-12 also increased the percentage of cytolytic T cells,DC, and F4/80⁺ macrophages. While single agent therapy elevated levelsof nitric oxide synthase 3-fold above basal levels in the tumor,combination therapy with MPL cationic liposomes and IL-12 stimulated a7-fold increase, supporting the observed cell cycle arrest (loss ofKi-67 expression) and apoptosis (TUNEL-positive). In mice bearing dualtumors, the growth of distal, untreated turners mirrored that ofliposome-treated tumors, supporting the presence of a systemic immuneresponse.

Experimental Details

Materials. MPL from Salmonella enteric serotype Minnesota RE 595 andcholesterol (Sigma grade≥99%) were purchased from Sigma-Aldrich (St.Louis, Mo., USA). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and1,2-dioleoyl-3-tri-methylammonium-propane (DOTAP) chloride salt wereobtained from Avanti Polar Lipids, Inc. (Alabaster, Ala., USA), MouseNovex Cytokine Magnetic 10-Plex ELISA kits were purchased fromInvitrogen (Grand Rapids, N.Y., USA). 4T1-luc2-td Tomato Bioware® UltraRed mouse mammary cancer cells were purchased from Caliper Life Sciences(Hopkinton, Mass., USA). Recombinant mouse IL-12 was purchased from R&DSystems, Inc. (Minneapolis, Minn., USA).

Animals. BALB/c mice (4 to 6-wks' old) were obtained from Charles RiverLaboratories, Inc. (Wilmington, Mass., USA). All procedures wereperformed in accordance with protocols reviewed and approved by allrequired institutional animal care and use committees.

Preparation and Characterization of Liposomes. DOTAP liposomes wereprepared using a molar ratio of 7:3:1 for DPPC:Cholesterol:DOTAP. Lipids(40 mg) were dissolved in a 3-mL chloroform:methanol (3:1) solution, and250 μg MPL (dissolved in chloroform at 5 mg/mL) was added. Organicsolvent was removed by overnight heating at 55° C. in a Hei-Vap® seriesFleidolph rotatory evaporator (Schwabach, Germany). The liposomes wererecovered in 2 mL PBS, followed by heating in a water bath at 52° C. for3 min, then vortexing for 3 min, and sonication for 30 sec. Theheat-vortex-sonication cycle was repeated 3 times, followed either byfinal sonication for 3 min to get the final liposome product, or byextrusion through dual filters (200 nm), 8×, using a 10-mL LIPEX®Thermobarrel Extruder from Northern Lipids, Inc. (Burnaby, BC, Canada).For liposomes containing cytokine, IL-12 was added to the hydrating PBSat a final concentration of 0.1 mg/mL. Adsorption of IL-12 to theliposomes was determined by quantitating the amount of IL-12 depletedfrom the solvent after removal of the liposomes by centrifugation usingthe BD™ Cytometric Bead Assay for mouse IL-12p70 (San Diego, Calif.,USA). Size and charge of liposomes were characterized by Dynamic lightscattering (DLS) and Zeta Potential analysis using a Zetasizer® (MalvernInstruments, Worcestershire, UK). Liposome size and shape were furthercharacterized by Atomic Force Microscopy using a MultiMode 8® SPM system(Broker Corp., Santa Barbara Calif., USA). AFM images were acquired inPBS in contact mode using MLCT cantilevers with a spring constant at0.01 N/m (Bruker).

Cootoxicky Studies. The cytotoxicity of cationic liposomes to 4T1 breastcancer cells was evaluated by flow cytometry using propidium iodide(PI). Using a 24-well plate format, cells were treated with 4 μg controlor MPL liposomes, or free MPL (250 ng) for 24 hr. Cells were releasedusing trypsin and treated with PI according to manufacturer's protocol(Invitrogen). Samples were analyzed using a LSR II® Flow Cytometer (BDBiosciences, Mountain View, Calif., USA) equipped with FACSDIVA™software (2007). In vivo tumor cytotoxicity of cationic liposomes wasevaluated in BALB/c mice bearing 200 mm³ 4T1 tumors 24 hr followingintratumoral injection of liposomes 50 μL; 1 mg lipid). Excised tumorswere embedded in paraffin, sectioned, and stained withhematoxylin/eosin, or analyzed for apoptosis using the DeadEnd®Fluorometric TUNEL System (Protnega Corp., Madison, Wis., USA).

Multiplex Bead ELISA, Serum cytokines were analyzed 5 hr afterintratumoral injection of liposomes using a mouse cytokine magnetic10-plex panel kit (Invitrogen, Carlsbad, Calif., USA) for the Luminex®platform. Following retro-orbital eye bleed, plasma was collected bycentrifugation at 1500×g for 10 min at 4° C. and stored at −80° C.Plates were prepared using 25 μL/well of the antibody-bound bead. After2 washes, 50 μL serum and 50 μL assay diluent (or 100 μL standard) wereadded and plates were incubated at room temperature for 2 hr on anorbital shaker. After two washes, 100 μL of biotinylated detectorantibody was added to the beads and they were incubated for anadditional hr, followed by two more washes and the addition of 100 μLstreptavidin-RPE for 30 min. After a final two washes, beads weresuspended in 125 μL wash solution and inserted into the XY platform of aLuminex® MAGPIX Instrument (EMD Millipore, Billerica, Mass., USA). Theassay protocol was designed using xPONENT software and samples were runat 100 events/bead region.

Immunohistochemistry. Tissues were quick frozen in OCT (Tissue-Tek) andstored at −80° C. Tissue sections (10 μm) were fixed with ice-coldacetone for 15 min at −20° C. and washed three times with 1× PBS usingtrays followed by blocking with 5% fetal bovine serum in PBS.Fluorescently-labeled antibodies [eFluor® 615 CD8 (clone 53-6,7; 1:50),eFluor® 570 Ki-67 (clone solA15; 1:100, eBioscience, San Diego, Calif.,USA), FITC F4/80 (MCA497A488,1:100), Alexa-Fluor® 647 CD204 (MCA1322;1:100, AbD Serotec, Raleigh N.C., USA); and 33D1 (1:100, BD Biosciences,San Jose, Calif.; 1:500 secondary anti-rat IgG Alexa-Fluor® 546;Invitrogen) and iNOS (6/iNOS/NOS; 1:100 BD Biosciences, San Jose,Calif., USA; 1:500 anti-rabbit IgG-TRITC, Jackson ImmunoResearchLaboratories, Inc., West Grove, Pa., USA)] were incubated with tissuesovernight at 4° C. in the presence of 5% FBS. Slides were then washedthree times with PBS and mounted with ProLong® Gold AntiFade® with DAPI(Invitrogen). Images were obtained using a confocal microscope (A1Nikon), and the percent-positive cells were determined by manualcounting of four arbitrary regions in random samples.

Therapeutic Efficacy Studies, Breast cancer tumors were established inBALB/c mice by intramammary injection of 1×10⁵ 4T1-luciferase cells.When tumors reached a median size of 100-200 mm³, mice were administeredintratumoral injections as follows: PBS control, Free MPL (6.25 μg),control liposomes (50 μL; 1 mg lipid); MPL liposomes (50 ∥L), and IL-12(5 μg) with/without MPL liposomes. Tumor growth was monitored by calipermeasurements three times per week and by luciferase expression measuredweekly using the Xenogen IVIS® Imaging System 200 Series (Perkin-Elmer,Inc., Waltham, Mass., USA) following intra-peritoneal injection of 75mg/kg RediJect® D-Luciferin (Perkin Elmer, Inc.). 24 to 26 days afterinitiation of tumor growth, mice were sacrificed, blood was collected byretro-orbital bleeding, and tumor and spleen were collected forimmunohistochemical, weight, and size analysis. Dual tumors were grownin naive mice using the same experimental conditions with intratumoralinjection of particles limited to a single tumor.

Results

Characterization of Cationic MPL Liposomes. In order to create localizednecrosis for release of tumor antigens and uric acid, a cationicliposome embedded with the TLR-4 ligand MPL was created. MPL favors aType 1 bias, supporting tumor regression, in immune responses. Dynamiclight scattering (FIG. 1A) supported an average diameter of 100.3±0.43and 103.3±1.85 nm for control and MPL-loaded liposomes, with apoly-dispersity index of 0.115±0.014 and 0.28±0.01, respectively. Toevaluate the heterogeneity of the population, liposomes were bound to anoxidized silicon wafer, with 3D images of the wafers display in FIG. 1B.The height image of the MPL liposomes (FIG. 1C) supported a dispersepopulation that was uniform in size. A line scan through the heightimage also supported homogeneity in size (FIG. 1D). The surfacepotential of the liposomes was approximately 47 mV for both control andMPL liposomes, supporting localization of MPL in the lipid bilayer (FIG.1E). Addition of rIL-12to the liposomes reduced the surface potential ofthe liposomes by 7 mV, supporting surface adhesion by rIL-12. Based ondetection of unbound IL-12 using a Mouse IL-12p70 Enhanced SensitivityFlex Set from BD Biosciences (R²=0.987 for standard curve), 34% and 26%of cytokine was in bound state for control and MPL containing liposomes,respectively.

Evaluation of Liposome Cytotoxicity To study particle cytotoxicity, 4T1cells were cultured with 4 μg/mL liposomes for 24 hr and cell death wasmeasured by flow cytometry based on propidium iodide (PI) uptake.Control and MPL liposomes induced cell death in 93% and 95% of thecells, whereas control and free MPL treated cells displayed 14% and 16%cell death, respectively (n=3; FIG. 2A). Flow cytometry histograms ofthe FL2 orange-red channel show a shift in the entire population ofliposome-treated cells (FIG. 2B).

The in vivo cytotoxicity of the cationic liposomes was studied in BALB/c4T1 orthotopic tumors. When the tumor volumes reached 100-200 mm³,intratumoral injections with PBS, free MPL, or liposomes were performed.After 24 hr, the mice were sacrificed and tumor tissue was analyzed byH&E and TUNEL staining. In contrast to control tumors, clear necroticregions were visible in mice treated with MPL liposomes (FIG. 2C).Minimal cell death was present in control and MPL-treated liposomesbased on TUNEL staining, while abundant cell death was present aftertreatment with both control and MPL liposomes (FIG. 2D).

Therapeutic Efficacy of Cationic Adjuvant Liposomes. To examine theimpact of cationic MPL liposome on breast tumor growth, 4T1 orthotopicbreast tumors were developed to a size of 100-200 mm³, and intratumoralinjections of liposomes were performed once a week for two weeks. Tumorgrowth was monitored by caliper measurements and luciferase expressionusing the Xenogen IVIS® Imaging System 200, and tumor weights weremeasured at the end of study. Despite inducing localized cell death,control cationic liposomes did not reduce the rate of tumor growth (FIG.3A). However, addition of MPL to the liposomes led to a dramaticreduction in tumor growth. Similar to control liposomes, free MPL didnot slow tumor growth (FIG. 3B). Bioluminescence imaging of luciferaseexpression following luciferin injection using the Senogen IVIS® ImagingSystem 200 supported the caliper data, with MPL liposome treatmentblocking tumor progression (FIG. 3C). The mass of excised tumors on day25 support a significant reduction in tumor growth following treatmentof MPL liposomes compared to both PBS and control liposome treated mice(FIG. 3D).

Combination Adjuvant Therapy Increases Blockade of Tumor Growth. Tocreate a microenvironment conducive to cell-mediated immunity our goalwas to boost the immune response further by adding rIL-12 to theliposome cocktail. IL-12, produced by macrophages and dendritic cells,stimulates proliferation and activation of cytotoxic CD8⁺ lymphocytesand NK cells, leading to the production of IFN-γ, and stimulatingantigen-specific and nonspecific immune responses.

Combined therapy with liposomal MPL and IL-12 (5 μg) was superior toeither agent delivered independently with respect to inhibiting tumorgrowth. While control liposome treated tumors were similar in size totumors in untreated animals, those treated with combination adjuvantwere unchanged from the start of treatment based on caliper measurements(FIG. 4A, n=5/group) and were undetectable in some animals bybioluminescence (FIG. 4B). An image of three randomly selected tumorsfrom each group is presented in FIG. 4C with the mean tumor weight andstandard deviation of all animals in each group presented in FIG. 4D.Serum cytokine measurements following single or combination therapysupported increases in IL-1β, IL-12, and TNF-α by all adjuvant therapy,with a significant enhancement by combination over single agent therapy(FIG. 4E). Only mice treated with IL-12 had an increase in serum IFN-γ.

Changes in the Cellular Phenotype of the Tumor Microenvironment. Tostudy phenotypic changes, and the impact on cell growth in the tumormicroenvironment following treatment with adjuvant particles, tissuesections were examined by immunofluorescence (FIG. 5A and FIG. 5B).Cellular proliferation, based on Ki-67 expression, was similar forcontrol and liposome treated animals (40%). However, addition of MPL tothe liposomes or injection with rIL-12 or MPL-IL-12-liposomes blockedproliferation (5-10%). The presence of CD8⁺ T cells in the tumor wasnegligible in control and liposomes-treated mice (0.8%), as were F4/80(7%) and iNOS (8%) expressing macrophages. Treatment withMPL-IL-12-liposomes led to significant increases in each of thesepopulations (28%, 36%, 54% for CD8+ T cells, F4/80 and iNOSmacrophages), as well as in 33D1+ dendritic cells. The percentage ofCD204 macrophages were not significantly altered in the tumors of twicetreated with adjuvant liposomes. In conclusion, MPL-IL-12-liposomesaugment infiltration of cytotoxic T cells and immune potentiating immunecells, and reduce proliferation of cells within the tumor,

Single Tumor Therapy in the Presence of Dual Tumors. MPL-IL-12-liposometherapy was administered to mice by intratumoral injection to inducecell death, block proliferation, and stimulate a cytokine and cellularmilieu conducive to anti-cancer immunity. Since the presence ofpro-inflammatory cytokines increased in the serum of treated mice, thepresence of systemic anti-cancer immunity was then assessed. Growth ofdistal tumors in mice receiving single tumor therapy was evaluated bycaliper measurements of tumor volume (FIG. 6A), tumor weight (FIG. 6B),and bioluminescence (FIG. 6C), based on luciferase expression in cancercells. For all groups, growth of the distal tumor mirrored that to thetreated tumor, with MPL-IL-12-liposome therapy inhibiting growth of thetumor.

Discussion

While the addition of MPL to cationic liposomes did not alter thesurface potential of the nanoparticles, addition of IL-12 caused a 7-mVreduction in the zeta potential, supporting surface presentation of thecytokine. The advantage of nanoparticle-based presentation of IL-12 wasreduction in serum levels, thus avoiding exposure to cytotoxic levels,and permitting a more sustained, localized release (Simpson-Abelson etal., 2009). The efficacy of using liposomal nanocarriers to reduce drugtoxicity, while enhancing immunity, has also been demonstrated for otheragents, such as amphotericin B in the fight against murine leishmaniasis(Daftarian et al., 2013).

While both control and MPL liposomes were toxic to cancer cells asanticipated, injection of MPL liposomes, unlike control liposomes,reduced cellular proliferation in tumors. The decrease in proliferationmay be attributed to increases in enzymes, such as iNOS, which wassignificantly upregulated in tumors following injection withMPL-liposomes. Activation of APC with pathogens or pathogen-specificmolecules (e.g., MPL) activates pathogen recognition receptors (PRRs),leading to release of effector molecules such as nitric oxide (NO)synthase (iNOS). NO has been shown to favor cell cycle arrest,mitochondria respiration, senescence or apoptosis (Napoli et al., 2013).While resting immune cells lack expression of iNOS enzyme, TLRengagement with CD14-LPS (or MPL) complex activates intracellularsignaling, which includes IRAK and MyD88 adaptors, leading to iNOStranscription (Lowenstein, and Padalko, 2004). In the present study, itwas shown that MPL liposomes and IL-12 induced small increases in iNOSexpression (3-fold), while combination therapy-with IL-12 and MPLliposomes synergistically increased iNOS expression (7-fold).

In addition to releasing tumor antigen complexes, dying cancer cellsrelease uric acid and lysosomal enzymes. These cellular components, aswell as MPL, activate the Nod-like receptor protein 3 (NLRP3)inflammasome (Martinon et al., 2006; Hornung et al., 2008). While NLRP3activation has been linked to infiltration by DC and macrophages, nosignificant increases were observed in either 33D1⁺ DC or F4/80⁺macrophages following treatment with MPL-liposomes. However, when IL-12was introduced into the liposomal formulation there were large increasesin DC, F4/80⁺ macrophages and CD8⁺T cells. NLRP3 activation stimulatessecretion of IL-1β and IL-18 (Dinarello, 2006).

It was previously demonstrated that porous silicon particle-basedpresentation of MPL in mice bearing 4T1 tumors augments its ability toincrease serum IL-1β levels, as well as other pro-inflammatory cytokinesincluding IL-12, TNF-α and IFN-γ (Meraz et al., 2012). In this study,MPL liposomes similarly increased serum levels of IL-1β, IL-12, andTNF-α. Addition of IL-12 led to a significantly greater increase in eachof these cytokines, and stimulated the production of INF-γ.

Cytokines patterns elicited by activated T cells favor eithercell-mediated immunity (i.e. T helper (Th)-1 biased), characterized byIFN-γ, IL-2 and TNF-α, or humoral immunity (Th-2 biased), characterizedby secretion of IL-4, IL-5, IL-6 and IL-10. IL-12 has potent anti-tumoreffects and has been shown to direct immune reactions from Th-2 to Th-3(Manetti et al., 1993; Sypek et al., 1993). As stated, IL-12 enhancedproduction of Th-1 cytokines and increased cytolytic T cells, DC andF4/80⁺ macrophages, as well as enhancing production of iNOS.Intratumoral administration of a combination of IL-12 and MPL liposomescompletely blocked 4T1 tumor growth. Combination liposomal therapy wasable to induce similar reductions in tumor growth in both treated anddistal tumors, suggesting a systemic immune response.

EXAMPLE 3

Chronic inflammation contributes to immune suppression within the tumormicroenvironment through a multitude of physiological changes, includingup-regulation of checkpoint inhibitors and alterations in the phenotypeand responsiveness of tissue immunocytes.

In vivo and ex vivo tumor imaging. Preliminary data was acquired usingthe orthotopic 4T1 murine model. Intravital confocal imaging of a TomatoBioware® Ultra Red tumor and FITC dextran-filled vasculature revealed alarge network of vessels at the tumor periphery (FIG. 7A). CT imaginganalysis of a tumor after perfusion with microfil revealed thatmacrovasculature is mostly localized at the tumor periphery (FIG. 7B).CT data were acquired on an Explore Locus SP (RS) pre-clinical SpecimenScanner (GE Medical Systems, London Ontario), a specimen-dedicatedcone-beam volume CT system with a tungsten source X-ray tube. Duringimaging, objects were rotated in 1.0-degree increments (360 views) on aholder between the X-Ray source and a CCD-based detector. The densityand location of microvasculature in tumor sections was defined by IHC(FIGS. 7C and D). Excised tumors were fixed, embedded in paraffin,sectioned, and stained with anti-CD31 antibody. Images were acquiredfrom labeled sections with the ImageXpress® Micro XL (Molecular Devices,Sunnyvale, Calif. USA) optical imaging system equipped with RGB filtersand a 10× objective. Micrographs were stitched together and maskscreated to enable us to quantitate vessels located in concentric ringsacross the tumor.

Tracking inflammation with MRI. Macrophage accumulation has beendocumented to contribute to cancer progression through suppression ofthe immune response and promotion of tumor vascularization (Mielgo etal., 2013). V-sense is a perfluorocarbon emulsion that is taken up bymonocytes and macrophages, allowing for in-vivo detection through ¹⁹FMRI. Ahrens, et al. (2011) successfully quantified V-sense in inflamedtissues of the central nervous system in an ex-vivo model of allergicencephalomyelitis, which they correlated with immunohistochemistry toconfirm co-localization of V-sense emulsion droplets and macrophages.Hitchens et al. (2011) detected perfluorocarbon-labeled macrophages in amodel of cardiac allograft rejection, which was confirmed viaimmunohistochemistry and histology. V-sense was used to study the impactof IL-12 on macrophage infiltration into the tumor (FIG. 8). In vitro,V-sense was taken up by RAW macrophages and ¹⁹F MRI revealed a positivecorrelation between cell number and signal intensity (FIG. 8A). Confocalimages in FIG. 8B show V-sense (red) uptake by Celltracker™ Green RAWcells. Merging of proton and fluorine images revealed differences intumor distribution 24 hours post IL-12 intratumoral injection, whencompared with sham control animals (FIG. 8C). Confocal micrographs oftumors extracted 24 hours post imaging supported strong penetration ofV-sense signal into tumor tissue as well as in the peripheral tumorregions of mice exposed to IL-12 (FIGS. 9A and C, left), while controltumors were limited to strong peripheral localization of NT-sense (FIGS.9B and C, right).

Immune phenotyping. Immunosuppressive regulators in the tumor include Tregulatory (Treg) and myeloid-derived tumor cells (MDSC). Tregs(CD4⁺/FoxP3⁺) and MDSC[CD11b⁺/Gr-1(Ly6-C/G)⁺] suppress effectiveantitumor immune responses. CD4⁺ and CD8⁺ T cells are the primaryadaptive immune cell mediators within the tumor and the proportion of Tcell subsets and DC present in the tumor plays a critical role in tumorrejection (Solheim et al., 2007; Zhao et al., 2012). Preliminary studiesshow that IL-12 decreases MDSC and increases CD4+ and CD8⁺ T cells inthe tumor 24 hours after treatment (FIG. 10).

REFERENCES

The following references, to the extent that they provide exemplaryprocedural or other details supplementary to those set forth herein, arespecifically incorporated herein in their entirety by express referencethereto:

Mielgo, A. & Schmid, M. C. Impact of tumour associated macrophages inpancreatic cancer. BMB reports 46, 131-138 (2013).

Ahrens, E. T., Young, W. B., Xu, H. & Pusateri, L. K. Rapidquantification of inflammation in tissue samples using perfluorocarbonemulsion and fluorine-19 nuclear magnetic resonance, BioTechniques 50,229-234 (2011).

Hitchens, T. K, et al. 19F MRI detection of acute allograft rejectionwith in vivo perfluorocarbon labeling of immune cells. Magneticresonance in medicine: official journal of the Society of MagneticResonance in Medicine/Society of Magnetic Resonance in Medicine 65,1144-1153 (2011).

Solheim, J. C., et al. Spleen but not tumor infiltration by dendriticand T cells is increased by intravenous adenovirus-Flt3 ligandinjection. Cancer gene therapy 14, 364-371 (2007).

Zhao, Y., et al. Hepatic stellate cells produce vascular endothelialgrowth factor via phospho-p44/42 mitogen-activated proteinkinase/cyclooxygenase-2 pathway. Molecular and cellular biochemistry359, 217-223 (2012).

AUDIBERT, F, “Adjuvants for vaccines, a quest,” Int. Immunopharmacol.,3(8): 1187-1193 (2003).

BARNIER-QUER, C et al., “Adjuvant effect of cationic liposomes forsubunit influenza vaccine: influence of antigen loading method,cholesterol and immune modulators,” Pharmaceutics, 5(3):392-410 (2013).

BRAUMULLER, H et al., “T-helper-1-cell cytokines drive cancer intosenescence,” Nature, 494(7437):361-365 (2013).

BREWER, J M, “(How) do aluminium adjuvants work? Immunol. Lett.,102(1):10-15 (2006).

CRAPARO, E F and BONDI, M L, “Application of polymeric nanoparticles inimmunotherapy,” Curr. Opin. Allergy Clin. Immunol., 12(6):658-664(2012).

DAFTARIAN, P M et al., “A targeted and adjuvanted nanocarrier lowers theeffective dose of liposomal amphotericin B and enhances adaptiveimmunity in murine cutaneous leishmaniasis,” Infect. Dis.,208(11):1914-1922 (2013).

DINARELLO, C A, Interleukin 1 and interleukin 18 as mediators ofinflammation and the aging process,” Amer. J. Clin. Nutr., 83(2):447S-455S (2006).

FACSDIVA Software V6.0, B. B., San Jose, Calif., USA (2007).

HALE, W G, and MARGHAM, J P, “HARPER COLLINS DICTIONARY OF BIOLOGY,”HarperPerennial, New York (1991).

HARDMAN, J G, and LIMBIRD, L E, (Eds.), “GOODMAN AND GILIMAN'S THEPHARMACOLOGICAL BASIS OF THERAPEUTICS” 10^(th) Edition, McGraw-Hill, NewYork (2001).

HORNUNG, V et al., “Silica crystals and aluminum salts activate theNALP3 inflammasome through phagosomal destabilization,” Nature Immunol.,9(8):847-856 (2008).

JAIME-RAMIREZ, A C et al., “IL-12 enhances the antitumor actions oftrastuzumab via. NK cell IFN-gamma production,” J. Immunol.,186(6):3401-3409 (2011).

KOOL, M et al., “Alum adjuvant boosts adaptive immunity by inducing uricacid and activating inflammatory dendritic cells,”J. Exp. Med.,205(4):869-882 (2008).

LAN, K H et al., “A DNA vaccine against cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4) prevents tumor growth,” Biochem. Biophys.Res Commun., 440(2):222-228 (2013).

LOWENSTEIN, C J and PADALKO, E, “iNOS (NOS2) at a glance,”J. Cell Sci.,117(Pt 14):2865-2867 (2004).

MANETTI, R. et al., “Natural killer cell stimulatory factor (interleukin12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses andinhibits the development of IL-4-producing Th cells,” J. Exp. Med.,177(4):1199-1204 (1993).

MARTINON, F et al., “Gout-associated uric acid crystals activate theNALP3 inflammasome,” Nature, 440(7081):237-241 (2006).

MERAZ, I M et al., “Multivalent presentation of MPL by porous siliconmicroparticles favors T helper 1 polarization enhancing the anti-tumorefficacy of doxorubicin nanoliposomes,”PIoS One, 9(4):e94703 (2014).

MERAZ, I M et al., “Activation of the inflammasome and enhancedmigration of microparticle-stimulated dendritic cells to the draininglymph node,” Mol. Pharm., 9(7):2049-2062 (2012).

MERAZ, F M et al., “Adjuvant cationic liposomes presenting MPL and IL-12induce cell death, suppress tumor growth, and alter the cellularphenotype of tumors in a marine model of breast cancer,” Mol. Pharm.,11(10):3484-3491 (September 2014).

MORI, A et al., “The vaccine adjuvant alum inhibits IL-12 by promotingPI3 kinase signaling while chitosan does not inhibit IL-12 and enhancesTh1 and Th17 responses,” Eur. J. Immunol., 42(10):2709-2719 (2012).

NAPOLI, C et al., “Effects of nitric oxide on cell proliferation: novelinsights,” J Am. Coll. Cardiol., 62(2):89-95 (2013).

NEEDLEMAN, S B and WUNSCH, C D, “A general method applicable to thesearch for similarities in the amino acid sequence of two proteins,” J.Mol. Biol., 48(3):443-453 (1970).

PHAN, G Q and ROSENBERG, S A, “Adoptive cell transfer for patients withmetastatic melanoma: the potential and promise of cancer immunotherapy,”Cancer Control, 20(4):289-297 (2013).

RIMANIOL, A C et al., “In vitro interactions between macrophages andaluminum-containing adjuvants,” Vaccine, 25(37-38):6784-6792 (2007).

SINGLETON, P and SAINSBURY, D, “DICTIONARY OF MICROBIOLOGY AND MOLECULARBIOLOGY,” 2^(nd) Ed., John Wiley and Sons, New York (1987).

SIMPSON-ABELSON, M R et al., “IL-12 delivered intratumorally bymultilamellar liposomes reactivates memory T cells in human tumormicroenvironments,” Clin Immunol., 132(1):71-82 (2009).

SYPEK, J P et al., “Resolution of cutaneous leishmaniasis: interleukin12 initiates a protective T helper type 1 immune response,” J. Exp.Med., 177(6):1797-1802 (1993).

WAN, S et at., “Chemotherapeutics and radiation stimulate MHC class Iexpression through elevated interferon-beta signaling in breast cancercells,”PloS One, 7(3):e32542 (2012).

WAYTECK, L et al., “A personalized view on cancer immunotherapy,” CancerLett., 352(1):113-125 (2013).

YAN, W et al., “Mechanism of adjuvant activity of cationic liposome:phosphorylation of a MAP kinase, ERK and induction of chemokines,”Mol.Immunol., 44(15):3672-3681 (2007).

It should be understood that the examples and embodiments describedherein are for illustrative purposes only and that various modificationsor changes in light thereof will be suggested to persons skilled in theart and are to be included within the spirit and purview of thisapplication and the scope of the appended claims. All references,including publications, patent applications and patents, cited hereinare hereby incorporated by reference to the same extent as if eachreference was individually and specifically indicated to be incorporatedby reference and was set forth in its entirety herein. Recitation ofranges of values herein are merely intended to serve as a shorthandmethod of referring individually to each separate value falling withinthe range, unless otherwise indicated herein, and each separate value isincorporated into the specification as if it were individually recitedherein.

The description herein of any aspect or embodiment of the disclosureusing terms such as “comprising,” “having,” “including,” or“containing,” with reference to an element or elements is intended toprovide support for a similar aspect or embodiment of the disclosurethat “consists of,” “consists essentially of,” or “substantiallycomprises” that particular element or elements, unless otherwise statedor clearly contradicted by context (e.g., a composition described hereinas comprising a particular element should he understood as alsodescribing a composition consisting of that element, unless otherwisestated or clearly contradicted by context).

All of the compositions and methods disclosed and claimed herein can hemade and executed without undue experimentation in light of the presentdisclosure. While the compositions and methods of this disclosure havebeen described in terms of certain embodiments, it will be apparent tothose of ordinary skill in the art that variations may be applied to thecompositions and methods and in the steps or in the sequence of steps ofthe method described herein without departing from the concept, spiritand scope of the disclosure. More specifically, it will be apparent thatcertain agents that are chemically- and/or physiologically-related maybe substituted for the agents described herein while the same or similarresults would be achieved. All such similar substitutes andmodifications apparent to those skilled in the art are deemed to bewithin the spirit, scope, and concept of the disclosure as defined bythe appended claims.

1-21. (canceled)
 22. A method for providing an antigen to a mammaliancell, comprising administering to a mammalian subject in need thereof,an effective amount of a cationic liposomal nanoparticle compositioncomprising: (i) a body, (ii) at least one outer surface; and (iii) atleast one reservoir inside the body, wherein the nanoparticle comprisesone or more toll-like receptor ligands (TLR-L), one or more distinctlipids, and an interleukin or other Type I cytokine on or about itsouter surface.
 23. The method of claim 22, wherein the mammalian subjectis at risk for developing, is suspected of having, or is diagnosed with,a tumor or a cancer.
 24. The method of claim 23, wherein the mammaliansubject is a human that has been diagnosed with breast cancer.
 25. Amethod of administering a diagnostic, therapeutic, or prophylactic agentto one or more cells, tissues, organs, or systems of a mammalian subjectin need thereof, comprising administering to the subject an effectiveamount of a cationic liposomal nanoparticle composition comprising: (i)a body, (ii) at least one outer surface; and (iii) at least onereservoir inside the body, wherein the nanoparticle comprises one ormore toll-like receptor ligands (TLR-L), one or more distinct lipids,and an interleukin or other Type I cytokine on or about its outersurface.
 26. A method of providing long-term protection against cancerrecurrence in a human, comprising administering to a human subject inneed thereof, an amount of a cationic liposomal nanoparticle compositioncomprising: (i) a body, (ii) at least one outer surface; and (iii) atleast one reservoir inside the body, wherein the nanoparticle comprisesone or more toll-like receptor ligands (TLR-L), one or more distinctlipids, and an interleukin or other Type I cytokine on or about itsouter surface and for a time effective to provide long-term protectionagainst cancer recurrence.
 27. The method of claim 23, wherein thenanoparticle comprises one or more TLR-4 ligands, optionallymonophosphoryl lipid A (MPL-A), and Interleukin-12 (IL-12) on or aboutits outer surface.
 28. The method of claim 23, further comprising atleast one cellular-targeting moiety comprising a chemical targetingmoiety, a physical targeting moiety, a ligand moiety, a ligand targetingmoiety, a geometrical targeting moiety, or an imaging agent, a contrastagent, a radiolabel, a chemotherapeutic agent, a targeting agent; or atleast one moiety selected from the group consisting of a ligand, adendrimer, an oligomer, an aptamer, a binding protein, an antibody, anantigen binding fragment thereof, a biomolecule, or any combinationthereof.
 29. The method of claim 23, wherein the at least one outersurface further comprises one or more dendritic cells, one or morecytokines, or any combination thereof.
 30. The method of claim 23,wherein the nanoparticle further comprises one or more antineoplasticagents, one or more other cytotoxic agents, one or more cytostaticagents, or one or more therapeutic or chemotherapeutic agents, or anycombination thereof.
 31. The method of claim 23, wherein thenanoparticle comprises DOTAP, DPPC, or cholesterol, or any combinationthereof.
 32. The method of claim 25, wherein the nanoparticle comprisesone or more TLR-4 ligands, optionally monophosphoryl lipid A (MPL-A),and Interleukin-12 (1L-12) on or about its outer surface.
 33. The methodof claim 25, further comprising at least one cellular-targeting moietycomprising a chemical targeting moiety, a physical targeting moiety, aligand moiety, a ligand targeting moiety, a geometrical targetingmoiety, or an imaging agent, a contrast agent, a radiolabel, achemotherapeutic agent, a targeting agent; or at least one moietyselected from the group consisting of a ligand, a dendrimer, anoligomer, an aptamer, a binding protein, an antibody, an antigen bindingfragment thereof, a biomolecule, or any combination thereof.
 34. Themethod of claim 25, wherein the at least one outer surface furthercomprises one or more dendritic cells, one or more cytokines, or anycombination thereof.
 35. The method of claim 25, wherein thenanoparticle further comprises one or more antineoplastic agents, one ormore other cytotoxic agents, one or more cytostatic agents, or one ormore therapeutic or chemotherapeutic agents, or any combination thereof.36. The method of claim 25, wherein the nanoparticle comprises DOTAP,DPPC, or cholesterol, or any combination thereof.
 37. The method ofclaim 26, wherein the nanoparticle comprises one or more TLR-4 ligands,optionally monophosphoryl lipid A (MPL-A), and Interleukin-12 (IL-12) onor about its outer surface.
 38. The method of claim 26, furthercomprising at least one cellular-targeting moiety comprising a chemicaltargeting moiety, a physical targeting moiety, a ligand moiety, a ligandtargeting moiety, a geometrical targeting moiety, or an imaging agent, acontrast agent, a radiolabel, a chemotherapeutic agent, a targetingagent; or at least one moiety selected from the group consisting of aligand, a dendrimer, an oligomer, an aptamer, a binding protein, anantibody, an antigen binding fragment thereof, a biomolecule, or anycombination thereof.
 39. The method of claim 26, wherein the at leastone outer surface further comprises one or more dendritic cells, one ormore cytokines, or any combination thereof.
 40. The method of claim 26.wherein the nanoparticle further comprises one or more antineoplasticagents, one or more other cytotoxic agents, one or more cytostaticagents, or one or more therapeutic or chemotherapeutic agents, or anycombination thereof.
 41. The method of claim 26, wherein thenanoparticle comprises DOTAP, DPPC, or cholesterol, or any combinationthereof.